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Abstract  
Background: Polypharmacy is an established risk factor for adverse drug events 
(ADEs) resulting from duplication of drugs in the same therapeutic class, drug-drug 
interactions, contraindicated and other inappropriate medication use. Such ADEs 
have a major impact the health of users of medicinal products. Japan is a major 
consumer country of drugs, however, few published studies have examined 
polypharmacy in Japan. 
Objectives: To describe the drug use patterns and to identify risk factors for 
polypharmacy in elderly persons in Hiroshima, Japan. 
Methods: This is a cross-sectional study, using secondary data of drug utilization in 
an elderly cohort from Hiroshima, Japan during October through December 2009. 
Polypharmacy was defined as the concomitant use of five or more drugs 
(prescription or over-the-counter). Study participants agreed to have all their 
medications reviewed by the attending pharmacists at participating sites and to 
provide information, including demographic (age, sex) and underlying diseases. The 
patterns of drug use were evaluated using descriptive statistics. Stepwise logistic 
regression models were utilised to identify factors (e.g., age, comorbidities, 
therapeutic drug class), independently associated with polypharmacy use. 
Results: A total of 452 persons (median age=76 years, 66% female) were included 
  iii 
in this study. Of these paesons, 70% met the definition for polypharmacy (median 
number of drugs=7, range=5 to 24). The following valriables were significantly 
associated with polypharmacy use: female sex, comorbidity score (Charlson 
comorbidity index), and use of at least one medication in certaion therapeutic 
categories (e.g., antihypertensives, vasodilators, peptic ulcer agents and others). 
Age and receiving prescriptions from multiple prescribers were not independent 
predictors of polypharmacy use. 
Conclusions: Age was not an independent predictor of polypharmacy among 
elderly people. Prevention strategies for ADEs resulting from polypharmacy should 
target sicker patients (i.e., comorbidities) and patients receiving care from multiple 
providers.  
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1 Introduction and background 
1.1  Introduction  
1.1.1 Aging society and active aging 
  The demography of Japan has changed considerably during the latter half of the 
20th century due to rapid economic growth in the period after the Second World War. 
As seen in Figure 1-1, the percentage of the population aged 65 years old or over, 
rose from less than 5% in 1925 to 14% by 1994 (Cabinet Office, 2010). This 
established Japan as an „Aging Society‟ as defined by Coulmas (2007). As of 
September 2010, individuals over 65 years of age comprised 23.1% of the 
population of Japan as of September 2010 (Ministry of Internal Affairs and 
Communication, 2010). This percentage is expected to continue to grow 
substantially over the next several decades and it is universally recognised that 
Japan is expected to become an „Aged society‟ the like of which no other country in 
the world has experienced. (Cabinet Office, 2009).   
  An “Aging Society” produces challenges for public health practitioners. As a result, 
the WHO (2010) has started to promote the 'Active Aging' framework to help health 
officilas to best prepare for the changing demographics in their locations. Some 
strategies suggested by the WHO include: “ensuring that older population have a 
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basic level of financial security”, “developing age-friendly environments”, assuring 
“availability and accessibillity of effective health care”, and “maintaining social 
patterns that influence the well-being of older adults” (WHO, n.d.a). In addition to 
hospitals and outpatient healthcare clinics, pharmacies can be a convenient setting 
for elderly people in a community to promote „active aging‟ in practice.  
 
1.1.2 Japanese health service policy and drug use 
 Japan ranks as one of the highest countries in terms of pharamceuticals 
consumption (Thompson 2011). It is argued that the growth of the elderly population 
along with the development of advanced medical technology increases in 
expenditures for medical care (Ministry of Health, Labour and Welfare (MHLW), 
2007). This is supported by the increase in percentage in national income spent on 
medical care from 6.1% in 1985 to 9.0% in 2005 in Japan (ibid.). Some notable 
features of healthcare and drug use in Japan is described as follows: 
Generic drugs: Some of the national and local policies in Japan aim to reduce drug 
expenditures by encouraging the use of generic drugs whenever possible (Japan 
Health Insurance Association, 2010, and Kure City, 2010).  
The increasing role of the pharmacy in healthcare delivery: The rate of 
dispensed prescriptions has increased an average of 62 percent in 2009 since the 
3 
MHLW annoucned the policy separating drug dispense from physician service in 
1958 (MHLW, 1958: MHLW, 2009c). The increased number of prescriptions 
dispensed would mean that there exist more opportunities for patients to connect 
with pharmacists. The contribution of pharmacists in healthcare delivery system is 
growing e.g., medication check-ups in a community pharmacy, ensuring the proper 
dosing, checking for drug-drug interactions. With such an aging society as in Japan, 
the support for medication management by pharmacists is expected to encourage 
the proper dosing of drugs in the elderly community. This could contribute to „active 
aging‟ as recommended by WHO (WHO, n.d.a).  In recent years, Japanese local 
pharmacies are being assessed for their involvement in health care for the elderly, 
including home care.  
Medical expenditure: Medical costs for elderly people in Hiroshima are higher than 
the national average in Japan (Figure 1-2). There are many survivors of the atomic 
bomb and their families living in Hiroshima, who are believed to consume more 
medical care than other areas given that they are exempt from payment by 
themselves for medical expenses.(Hiroshima city, 2009) (Figure 1-3). All Japanese 
people are required to join a health insurance organisation for employees, the 
publich health insurance by region, or the national health insurance system for the 
elderly aged 75 and over (MHLW, 2007). 
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Figure 1-1 Trend of the increase of aged population 
 
Source: Population Division of the Department of Economic and Social Affairs of the 
United Nations Secretariat, World Population Prospects: The 2008 Revision, 
http://esa.un.org/unpp, September 19, 2010. 
 
Figure 1-2  Map of medical expenses for the elderly (average of prefectures =1.00). 
(Adopted from MHLW, 2009a) 
 
Hiroshima is circled in red. 
Ratio of medical expenses for the elderly (Average =1.00) 
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Figure 1-3 Graph of items of medical expenses for the elderly per capita 
(adopted from MHLW, 2009b) 
 
Hiroshima is circled in red. 
 
1.1.3 Brown Bag Programme in Hiroshima 
  A medication use review programme was was developed recently in Japan  to 
promote health and the rational use of medicines among Japanese citizenes, with 
particuler focus on elderly persons (http://plaza.umin.ac.jp/~brownbag/). This 
program, known as Brown Bag Programme, was developed by a regional pharmacy 
association and supported by the University of Tokyo and is modelled after the Brown 
Bag Programme in the US (Nathan, 1999; Department of Health and Human 
Services, 1995) and Medicine Use Review (MUR) in the UK (NHS Primary Care 
White: Others 
Gray: Dentist 
Red: Outpatient and medicines 
Blue: Admission, room and board 
Dot: Medical cost par capita 
Medical expenses for the elderly  
Cost differences from the average (ten thousand yen) 
National Average = 869,604yen 
 
Max: Fukuoka 1,082,157yen 
Min: Nagano 715,564yen 
(1.51times) 
D
iffe
re
n
c
e
 to
 th
e
 n
a
tio
n
a
l a
v
e
ra
g
e
  
(1
0
 th
o
u
s
a
n
d
 y
e
n
 
6 
Contracting, 2007). Through the Programme, participating pharmacies performed 
drug use survey for prescriptions, OTC drugs and supplements among their 
customers. The present analysis examines data from collected through the Brown 
Bag Programme in the Hiroshima Prefecture in 2009, through October to December. 
In preliminary analysis of the Hiroshima Prefecture data, elderly participants took, on 
average, 6.6 prescription drugs, 1.6 OTCs and 1.8 supplemental health products 
(Kusama, 2010). Furthermore, 62% of the participants in this program took more 
than 5 prescribed medicines (ibid); Slightly over one-third (35 %) of participants 
routinely took OTC products and over one-half (53%) routinely used nutritional 
supplements. Based upon these preliinary data, Kusama (2010) suggested that such 
programs (through the intervention of pharmacists) could help to mitigate the risk of 
drug overdoses or interactions.  
 
1.2  Literature search strategy 
The literature search aimed to identify articles that addressed the following 
questions (1) what is polypharmacy, (2) what are health issues relating to 
medications among elderly people, (3) what are risk factors of polypharmacy and (4) 
which approach has been taken to analyse predictors of polypharmacy.  
 English language literature sources included PubMed, the World Health 
7 
Organization (WHO), Google Scholar, and computerised suggestions provided by 
the online Library of the University of Liverpool (SFX by Ex Libris Inc.) was 
considered to examine relevant articles when appropriate. For Japanese language 
literature, the MHLW and the Scholarly and Academic Information Navigator 
provided by the National Institute of Information (http://157.1.40.181/) were used. 
The references of relevant articles were also reviewed for both English and 
Japanese articles that might be relevant to this study. As the word “Tazaiheiyou” 
(“polypharmacy” in Japanese) is so frequently used to describe typical 
chemotherapy regimen and psychiatry treatments, articles in the areas of oncology 
or psychiatry were excluded from literature review. The latest yearly reports of the 
MHLW were reviewed first, then chronologically checked if necessary.  
 Search terms used in the literature search and the numbers of articles identified 
through thise search strategies are shown in the Table 1-1 (note: Google Scholar 
results are not shown due to too many non-relevant hits). A total of 3052 articles 
were identified in PubMed when searching with “polypharmacy” only, and 220 in 
WHO. The search was refined with terms “definition”, “”elderly people”, “risk factor”. 
Most of articles described specific diseases and were removed afterwards. Some 
were not available to obtain. As a result, 18 remaining articles are summarised in the 
following section.  
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Table 1-1 Literature search results, excluding literatures aiming at specific 
disease 
Search words Source Results 
(1) how polypharmacy is defined 
“polypharmacy (tazaiheiyou)”, “definition 
(teigi)” 
PubMed 31 
WHO 155 
CiNII 0 
(2) what are health problems relating to polypharmacy among elderly people 
"polypharmacy (tazaiheiyou) ", "elderly 
people (koureisha)" or "older people 
(koureisha)" and “problem (mondai)” 
PubMed 123 
WHO 97 
CiNII 
8 (EN) 
25 (JP) 
MHLW 219 
(3) what are risk factors of polypharmacy 
"polypharmacy (tazaiheiyou)", "elderly people 
(koureisha)" or "older people (koureisha)",  
"risk factor (youin)" 
PubMed 89 
CiNII 0 
(4) which approach has been taken to analyze predictors of polypharmacy. 
""polypharmacy (tazaiheiyou)", "elderly 
people (koureisha)" or "older people 
(koureisha)",  “predictor"  
PubMed 11 
 
CiNII: the Scholarly and Academic Information Navigator provided by the National 
Institute of Information 
MHLW: Ministry of Health, Labour and Welfare 
WHO: World Health Organization 
A term or phrase in parenthesis is Japanese translation. 
 
1.2.1 Definition of polypharmacy  
  There are multiple definitions of polypharmacy utilized in the literature (Table 1-2).  
Furthermore, some investigators include only prescription products in defining 
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polypharmacy, while others include OTC medicines as well. The four literatures 
studing on predictors of polypharmacy applied the definition of „polypharmacy‟ as the 
concurrent use of five or more prescription drugs (Junius-Walker et al, 2006; 
Rozenfeld et al. 2008; Harugeri et al. 2010; Nobili et al. 2011), while prescribing of six 
and more drugs was applied by Jyrkka et al. (2009a, 2009b). No definition was found 
for „tazaiheiyou‟, polypharmacy in Japanese in the literature.  
 
Table 1-2 Definitions of ‘polypharmacy’, derived from Fulton and Allen (2005) 
Multiple definitions of „polypharmacy‟ appearing 
in the literature 
Authors 
Two or more drugs for 240 days or more  Veehof et al., 2000 
Concurrent use of two or more drugs  Bjerrum, 1998 
Use of four or more medications  Bikowski, Ripsin, & Lorraine, 2001 
Use of five or more different prescription 
medications 
Jorgensen et al., 2001,  
Linjakumpu et al., 2002 
Regular daily consumption of multiple 
medications as well as the use of high-risk 
medications and questionable dosing 
Golden et al., 1999  
 
 
untoward iatrogenic sequelae of the use of 
multiple, interacting medications  
Fillit et al., 1999, p. 587 
 
1.2.2 Disease and medication for older people 
 An increase of older people may reflect improvement in human health as a result of 
better hygiene and advanced health technologies. Ironically however, in an aged 
society, the proportion of individuals suffering from many chronic diseases increases 
with age(Hawthorne, Greaves and Beevers, 1974 in Martin and Coleman, 2007).  In 
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Japan, in particular, the incidence of chronic illnesses, such as diabetes and 
hypertension, has risen in parallel with the rising age distribution of the population 
(MHLW, 2008). There is a corresponding increase in use of medications to manage 
these chronic illnesses and some patients with multiple conditions require numerous 
medications long-term. Therefore it is not uncommon for an older Japanese 
outpatient to take more than ten different drugs (Yasuhara et al., 1980). 
  There are some well known issues in pharmacotherapy for elderly patients. Firstly, 
changes of pharmacokinetics (absorption, distribution, metabolism and renal 
excretion) and pharmacodynamics (e.g. sensitivity to a given dose of drug) occur in 
elderly people due to changes of constitution and physiology with age (Martin and 
Coleman, 2007). Regulatory bodies in Europe, the US, and Japan have advocated 
for investigating the efficacy and safety of drugs in elderly persons through 
well-designed randomized clinical trials (International Conference on Harmonisation 
on Technical Requirements for Registration of Pharmaceuticals for Human Use, 
1993). However, more often than not there is a limited amount of useful evidence 
regarding the effects of medicines in the elderly (Martin and Coleman 2007).   
  Secondly, elderly persons often require the use of medicines on a long-term basis 
to manage chronic diesases (ibid). For example, US Centers for Disease Control and 
Prevention (CDC) (2003) estimated that approximately 80% of people aged 65 years 
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and older in the US have at least one chronic disease.  
  Lastly, gIven that older patients often have multiple concurrent illnesses (Hajjar et 
al. 2007; Masoodi, 2008), they were more likely than younger persons to take 
multiple medicines, which, as will be discussed, increases the chances of drug-drug 
interactions and inappropriate medication use (Hajjar et al. 2007; Martin and 
Coleman, 2007).  
 
1.2.3 Risk factors of polypharmacy  
 Those potential issues addressed above were considered risk factors for increased 
adverse drug reactions in the elderly population (Beyth and Shorr, 1999, Martin and 
Coleman 2007). In a study from Japan, Koyama et al. (2003) reported that the 
number of potential drug-drug interactions is correlated with the number of 
concomitant drugs being taken. This finding is especially disconcerting given that the 
authors reported that 28% of elderly (65+ years) outpatients at a university hospital 
took six or more medications concurrently.  
  The more complicated a treatment regimen, the worse the adherence to that 
regimen (Murry and Kurt, 2001; NCPIE, 2007). There is considerable controversy 
regarding medication compliance in older patients, with reports of both better and 
worse compliance in older patients as compared to younger patients (Akishita, 1995; 
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Takami, 2000; Rottander et al. 2007). Non-compliance and evaluating health status 
as ‟no improvement‟ may lead a physician to prescribe more of the same or another 
medicine to treat a disease. 
 
1.2.4 Predictors of polypharmacy studied by others 
  Several investigators have researched the predictors of polypharmacy in a variety 
of settings and geographic locations (Table 1-3): Junius-Walker et al. (2007) in 
Germany, Rozenfeld et al., (2008) in Brazil, Harugeri (2010) in India and Nobili (2011) 
in Italy.  
  Junius-Walker et al. (2007) described that 3.7 prescribed medicines and an 
additional 1.4 OTC drugs on average were consumed among 466 participating 
patients aged 70 and older in a German community. They combined medication   
and socio-demographic variables into a logistic regression moedel, and identified 
five predictors of polypharmacy (as defined as five and more prescribed medicines in 
their study) such as breathless, hypertension, instrumental activities of daily living, 
low perceived health, and a medication disagreement between doctors and patients. 
Harugeri et al. (2010) investigated predictors of polypharmacy in 814 admitted 
patients aged 60 to 95, analysing by multivariable logistic regression. In their 
research, three and more diagnoses, angina pectoris, and length of stay were found 
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to be predictors of polypharmacy with 10 and more drugs. In distinction from the 
result of Junius-Walker et al., they did not find significant association between 
polypharmacy and respiratory problem such as COPD. Rozenfeld et al. interviewed 
800 retirees regarding their medications and found 3.7 products were administered 
on avarage. They tested the significance of the association between polypharmacy 
and variables relating to disease and health care. Hypertension and diabetes 
patients showed the highest prevalence of polypharmacy. Age, with improved social 
and economic conditions and worsening state of health were likely to increase the 
number of drugs used. With limited statistical power, it was difficult to evaluate the 
association between drug use and economic/social variables. Among inpatients in 
Italy, Nobili et al. (2011) reported that 51.9% of patients at admission and 67.0% of 
patients at discharge were identified as receiving polypharmacy. The average 
number of prescription drugs per patient was 4.2 at admission and 6.0 at discharge. 
Predictors of polypharmacy at discharge in this study were age, number of drugs at 
admission, hypertension, ischemic heart disease, heart failure, and COPD.  
 Some of these studies controlled for socioeconomic (SES) factors such as 
education and income, while others did not take into account SES variables. From 
the published research presented in Table 1-3, the number of drugs consumed per 
person was higher in hospital than in community. As pointed out by Nobili et al. 
14 
(2011), the characteristics of the study cohort containing hospital data are biased, in 
that it often does not include OTC drugs and supplements.  
 In Japan, surveys have been published describing problems linked to polypharmacy 
within clinical psychiatric practice (Takei et al. 2002), elderly hospital outpatients 
(Suzuki et al. 2006; Yasuhara et al 1980) and home-care patients (Takami , 2000), 
These authors discuss problems relating to polypharmacy rather than predictors of 
polypharmacy.  
  In conclusion, there are few studies that have examined predictors of 
polypharmacy as a whole. A modest amount of research has considered the extent to 
which factors such as age and comorbidity status influences the risk of polypharmacy 
(Yasuhara et al., 1980). Finally, most of the research that has been done on 
polypharmacy has focused on prescription products only, ignoring OTC medications 
and nutritional supplements.  
 
Table 1-3: Literature review regarging predictors of polypharmacy among elderly 
people 
 Junis-Walker et al. (2006) Rozenfeld et al. (2008) 
Aim To describe prescribed and OTC 
medicines use, to determine 
predictors of polypharmacy 
To describe drug use focusing on 
inappropriate use 
Country Germany Brazil 
Subjects ≥70 , male and female 
 
≥60 , male and female recipients of 
benefits 
Setting Primary care Social insurance 
15 
Sample size 814 577 
Age  Mean Male:77.0 Female: 76.3 NA 
Sex Male 493 (60%) Female (40%) Male 225 (39%) Female (61%) 
Sampling Questionnaire to patients and GPs Database established from   
interviews  
Polypharmacy ≥5 prescriptions  
26.7% 
≥5 prescriptions 
32.7% 
Number of 
diagnosis (SD) 
None≤ ≤2 
3 or 4 
5≤ 
CCI 
 
NA 
420 (51.6%) 
338 (41.5%) 
56 (6.9%) 
NA 
 
NA 
201 (34.9%) 
243(42.2%) 
132(22.9%) 
NA 
Common 
disease(N, %) 
Hypertension  37.2% 
Diabetes 28.9% 
Chronic Bronchitis 11.3% 
Atrial fibrillation/arrhythmia 9.2% 
Hypertension 59.9% 
Diabetes 17% 
Bone and articular disease 42.6% 
Number of drugs 
(Mean) 
Prescription 3.7  
OTC 1.4  
3.7 (SD=2.9) 
 
Common drugs 
(%) 
NA A11: Vitamins 8.1% 
B01: Antithrombotic 4.7% 
C03: Diuretics 9.2% 
C08: Calcium-channel blockers 
4.7% 
C09: Renin-angiotensin system 
8.2% 
N02: Analgesics 4.2% 
S01: Ophthalmologicals 4.7% 
Statistical Method Logistic regression model with 
stepwise forward selection,  
adjusted by age and sex 
Pearson chi-square test for 
differences on proportions 
Factors 
Associated with 
polypharmacy 
Breathlessness, hypertension, 
dependent on instrumental 
activities of daily living, perceived 
health, medication disagreement 
between patient and doctor * 
Age, improved social and economic 
conditions e.g. private health 
coverage, worse health status 
 
Continued: 
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 Harugeri et al. (2010) Nobili et al. (2011) 
Aim To assess prescribing patterns and 
to determine predictors of 
polypharmacy 
To evaluate the prevalence and 
factors associated with 
polypharmacy, to investigate the 
role of polypharmacy as a predictor 
of length of hospital stay and 
in-hospital mortality 
Country India Italy 
Subjects ≥65 , male and female 65≥, male and female 
Size of population 814 1332 at admission, 1155 at 
discharge 
Setting Hospital Hospital, at admission and ad 
discharge 
Age  Median 66 (60-95) Mean 79.4 (SD=7.5) at admission 
Sex Male 493 (60%) Female 321(40%) Women 52.5% at admission, 53.5% 
at discharge 
Polypharmacy ≥5 prescriptions  
90.4% 
≥5 prescriptions 
51.9% at admission, 67.0% at 
discharge 
Sampling Medical record Prescription data 
Number of 
diagnosis (Mean) 
None≤ ≤2 
3 or 4 
5≤ 
CCI  
 
NA 
420 (51.6%) 
338 (41.5%) 
56 (6.9%) 
NA 
5.2 (SD=2.3) at admission, 5.9 
(SD=2.5) at discharge 
 
 
 
CCI 0.5 (SD=0.8) 
Common 
disease(%) 
Hypertension  42.4% 
Diabetes 35.7% 
COPD  18.8% 
Angina pectoris 75, 9.2% 
Hypertension 57.8% 
Diabetes 24.0% 
Coronary heart disease 23.0% 
Atrial fibrillation 20.6% 
COPD 20.0% 
Cardiovascular disease 19.5% 
Number of drugs  Median Male:9.0 Female: 9.0 4.9 (SD=2.9) at admission, 6.0 
(sd=2.9) at discharge 
17 
ATC: Common 
drugs (%) 
A02: Acid-related disorder 69.2% 
A10: Diabetes 38.6% 
B01: Antithrombotic 42.6% 
C03: Diuretics 28.3% 
C08: Calcium channel blockers 
28.3% 
C09: Renin-angiotensin system 
25.2% 
C10: Lipid-modifying 26.9% 
J01: Antibacterials 70.5% 
N02: Analgesics 36.9% 
R03: Obstructive airway disease 
41.2% 
A02B: Peptic ulcer and GERD 
41.0%, 56.0% 
A10B: Blood glucose lowering 
drugs 15.4%, 14.6% 
B01A: Antithrombotic 52%, 59.7% 
C03C: High ceiling diuretics 34.9%, 
39.3% 
C09A: ACE inhibitors 27.0%, 31.3% 
C07A: Beta-blocker 25.1%, 28.5% 
C10A: Lipid modifying 17.3%, 
18.2% 
Statistical Method Multiple variable logistic regression 
model 
Linear regression to evaluate 
predictors of length of hospital stay 
Logistic regression models for 
predictors of in-hospital mortality 
Factors 
Associated with 
polypharmacy 
Number of diseases, angina 
pectoris, length of stay 
At discharge: age, number of drugs 
at admission, hypertension, 
ischemic heart disease, heart 
failure, and COPD 
*social problems do not show a significant difference  
CCI: Charlson Comorbidity Index 
 
1.3  Research question 
1.3.1 Epistemological aspects on polypharmacy 
 A positivist epistemology was adopted in this dissertation exploring risk factors of 
polypharmacy among the elderly people in community in order to reduce risks 
caused by concurrent use of multiple medications and to improve active aging. Eldely 
persons were defined as those over the age of 65 years according to the international 
definition commonly accepted in developed countries (WHO, n.d.b). And 
18 
polypharmacy was defined in this study as the use of five and more drugs 
(prescription and OTC). This study is unique in that it focuses on drug use in the 
community setting, whereas most of other investigations were conducted in hospital 
setting and therefore focused only on prescription medicines.  
 Based on litarature review, the assumption was made that the elderly people in 
Japan is prone to receive multiple medications due to certain factors such as relating 
to gerontolgy and specific diseases. Information on influence by socio-economic 
condition was scarce. Health care service is one of known determinant of heatlh 
(Dahlgren and Whitehead, 1991 cited in Naidoo and Wills, 2000:p29), and 
polypharmacy plays a part. Although every factors might contribute polypharmacy to 
some extent, there is no studies to investigate causal relationship (with time-scale) 
between such factors and polypharmacy. Before conducting a londitidual research, a 
cross-sectional study would be more appropriate to describe the current condition of 
polypharmacy and the association between possible factors and polypharmacy. In 
other words, the null-hypothesis is suggested that each factor (independent variable) 
has no significant association with polypharmacy among the elderly Japanese 
people.  
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1.4 Possible data source of medication use 
 To obtain information of medication use at community level, there were several 
sources available. One is a health insurance database. It is also possible to detect 
possible inappropriate prescriptions and polypharmacy or to describe medication 
use by retrospectively analyzing a medicines receipt database (Akazawa et al., 2009; 
Brown et al., 2007). The other is a data in the setting of a family pharmacy, one can 
check whether the quantity and selection of drugs is based on an appropriate 
regimen. Moreover, it would be possible to retrieve information such as the use of 
OTC drugs and supplements, e.g. obtained by the Brown Bag Programme, which 
cannot be obtained from the receipt data. Thus, in this study, a secondary data from 
the Brown Bag Programme in Hiroshima was investigated. 
 
1.5 Study aims 
 Aims of this study are: 
 To describe the patterns and potential safety issues related to prescription and 
OTC drug use in the elderly in Hiroshima, Japan.  
 To identify predictors for polypharmacy defined as the concurrent use of 5 or more 
medicines, among elderly persons.  
 To identify the potential for safety issues related to specific drug use patterns (e.g. 
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drug-drug interactions and possibly inappropriate mediction) 
 
2 Methods 
2.1 Data Sources 
Brown Bag Programme 
  The study group promoting the Brown Bag Programme 
(http://plaza.umin.ac.jp/~brownbag/) called for pharmacies through the Hiroshima 
Pharmacy Association (HPA) to provide results of medication review. As reported by 
Kusama (2010) and Akazawa et al. (2011 to be published), the Brown Bag 
Programme involved elderly participants being encouraged to bring all their 
medicines, including OTC drugs and dietary supplements, to community pharmacies 
for evaluation of potential safety problems. Additionally the participants voluntarily 
gave information on their actual drug usage which allowed pharmacy personnel to 
use this opportunity to evaluate adherence to prescribed instructions. Personal 
information of participants was anonymously provided at the pharmacy, and the 
results of the medication review were submitted to HPA. The study group of 
University of Tokyo obtained the submitted data from the HPA, which built a database 
on obtained data and analysed drug use patterns and subsequent issues including 
contraindications, interactions and adverse events. 
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 The medication review was conducted at participating pharmacies and the results 
were recorded in a standardized format with defined data elements (Appendix1 and 
3) including: patient information (i.e. age, sex, type of health insurance, the number 
of routine visits to health institutes, underlying disease, how to obtain pharmaceutical 
products, reason for taking OTC drugs and dietary supplements, reason for receiving 
medication review and an perception of receiving medication review) and the results 
of the medication review by a pharmacist (i.e. when, where, who and how long it was 
taken, observed issues such as potential drug-drug interaction). Of which, data listed 
in Appendix 3 were used in this study: demographics and self-reported underlying 
diseases.  
  Appendix 2 shows the form for recording medicines used including OTC drugs and 
dietary supplements, along with other information pertaining to the medications, such 
as storage, adherence and action taken when a dose is missed. The participating 
pharmacist filled in the form and sent it to the study group of the University of Tokyo. 
Appendix 4 shows the dataset interpolated into this study from Appendix 2. The study 
group encoded each product name or ingredient by use of a 12-letter code known as 
the MHLW medicinal product code (MHLW, 2010a). 7-digit number from the left of 
this code represents its ingredient and category, for example 1112700: Halothane, 
1127: halogen hydrocarbon, 112: anesthesia, 11: central nerve system. An external 
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medicine which is topically use or single use as needed was excluded from encoding 
process, since these medicines rarely cause notable safety issues related to 
polypharmacy. 
IMS National Prescription Audit (NPA) 
  The datasets and medicine claim codes have been defined by the MHLW (MHLW, 
2010b), which were applied by all medical institutes in Japan including pharmacies to 
the Health Insurance Claims and Review, Reimbursement Services. IMS Japan K.K. 
developed their database, „IMS NPA Family‟, based on dispensing information 
provided by pharmacies formatted in the nationally defined dataset of claims (IMS 
Japan K.K., n.d.). They integrated the claims data from the pharmacies and also 
added information obtained from other sources such as Anatomical Therapeutic 
Chemical (ATC) classification (WHO Collaborating Centre for Drug Statistics 
Methodology, 2010), and information on hospitals issuing prescriptions. IMS Japan 
K.K. and K.Nomura agreed upon the confidentiality and data specification for this 
study. The dataset provided by IMS Japan K.K. was sufficient to describe medication 
use of each person; drug code, 4-digit of ATC code, dose form, patientID, gender and 
age group. The provided data included anonymous patient information (i.e. age, sex), 
medicines (e.g. drug code, strength, dosage form, dispensing date etc.), instruction 
given to a patient from the dispensing pharmacy (represented by additional fees), 
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and pharmacy and hospital information. Information relating to patient and medicines 
use was only used in this study, presented in Appendix 5.  
 
2.2 Study design 
 The present study was a cross-sectional analysis of medication use in elderly 
persons in Hiroshima, Japan in the fourth quarter of 2009. The data for analysis were 
collected from two primary sources.  
 The Brown Bag Programme conducted in Hiroshima, Japan, between October 
and December 2009.  
 The medicinal claims data from IMS Japan K.K., data from this source were used 
to validate the generalizeability of the information collected through the Brown 
Bag Programme. 
 
2.3 Inclusion/Exclusion criteria of participants 
Brown Bag Programme 
  The study sample is based upon persons recruited as part of the Hiroshima Brown 
Bag Programme. In total, 530 participants including those who were younger than 65 
years old participated to the programme. Potential participants were asked to visit the 
one of the pharmacies taking part to the study in order to to receive their medication 
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review. Therefore those who were taken care of at home or at hospital were not 
included in the analysis. Of the 530 participants, 45 persons younger than 65 years 
old, 7 persons with unknown age, and one person with unknown sex were excluded. 
In addition, 18 participants who did not provide any health information addressed in 
Appendix 1 were excluded from the analysis. Finally, if the participant did not provide 
any prescription or OTC information, the observation was omitted (N=7) (Figure 2-1). 
The remaining 452 of individuals were studied in the analysis. 
IMS NPA 
 IMS Japan K.K. provided data items under the agreement, which were extracted 
from their NPA database. These data included information on persons aged 65 years 
old and older who received prescription medicines at pharmacies in Hiroshima 
through October to December in 2009 (Figure 2-2). There were 22,470 subject 
patients in total. Age data were stratified into eight ordinal categories by 5-year 
intervals (aged 65-59, 60-64, 65-69, 70-74, 75-79, 80-84, 85-89, 90+) based upon 
the birth date recorded in the original claims data.  
 
 
Figure 2-1 Flowchart for available data from Hiroshima Brown Bag Programme 
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Figure 2-2 Flowchart for available data from IMS NPA, from October to December 2009 
 
 
2.4 Definitions of variables for analysis 
In this study, several specific terms were used as defined below. 
1. Polypharmacy 
Polypharmacy for this study is defined as the use of five or more than five types of 
medicines concurrently (prescription drugs and/or OTCs). 
Recruited	par cipants	
N=530 
Number	of	drugs	1-4	
N=137	
Number	of	drugs	5≤	
N=315 
Without	Pa ent	Feedback	
Sheet	
N=18 Age	unknown		N=7	
≤64	yeas	old	N=45 
Sex	unknown	N=1 
No	drug	use	
	(dietary	supplement	only)	
N=7 
Pa ents	aged	65	and	older	
N=22470 
Number	of	drugs	1-4	
N=13853	
Number	of	drugs	5≤	
N=8617 
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2. Number of visiting medical facilities 
A participant reported the number of medical facilities that he/she was visting at 
that time.  
3. Charlson Comorbidity Index 
This was developed by Charlson et al. (1987) to measure prospectively the risk of 
1-year mortality based on a longitudinal study of general hospitalized patients. 
Nobili et al. (2011) included values derived from the Charlson comorbidity index 
as variables to evaluate predictors of length of hospital stay, as well as acting as a 
dummy variable of polypharmacy. CCI was proposed by Charlson et al. (1987), 
and was assembled as follows. 15 self-reported diseases were recorded based 
on the predefined form (Appendix 1). Through use of self-reported diseases, 
severity of comorbid conditions was estimated in figures derived from CCI. Briefly 
the CCI assigns points for each comorbid condition, with more serious conditions 
receiving higher points (Table 2-1). In turn, a higher score on the CCI indicates 
increased seriousness of comorbid conditions. To keep the statistical power at a 
certain level when there are too many variables, it is needed to increase the 
number of subjects or to decrease the number of independent variables (Katz, 
2006:p81). Many disease variables were integrated into one CCI.  
4. Duplicate drugs 
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Detection on duplication of drugs was systematically provided by an IT vendor 
company (System Yoshii, Co. Ltd.), using the Japan unique drug identifier (7 digit 
code) that represents an active ingredient or a combination of active ingredients. 
5. Contraindications and Interactions 
Detection on drug-drug interactions was systematically provided based on 
regulated drug information by an IT vendor company (System Yoshii, Co. Ltd.). 
 
Table 2-1 Charlson Comorbidity Index 
 
Table was adopted from McGregor et al. (2010) 
 
2.5 Descriptive analysis 
  Age obtained by the Brown Bag Programme was analysed as a continuous 
variable and was also categorized into the same intervals as the IMS data (i.g., 65-69, 
70-74, 75-79, 80-84, 85-89 and 90+ years). Other information on a participants‟ 
background included continuous variables (number of medical facilities, Charlson 
comorbidity index), dichotomous (female, each reported disease etc.) and text 
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(Participant ID). The category of a prescription drug was encoded by use of the 
MHLW medicinal product code for the Brown Bag Programme and of ATC 4-digit 
code for IMS NPA data as described above in 2.1.  
 Note that polypharmacy was defined as „5 or more medicines‟ and OTC information 
was available in the Brown Bag Programme, but not in the IMS NPA. The Brown Bag 
Programme is a cross-sectional study, but IMS NPA has patients who received 
medicines several times during the study period. Patients with polypharmacy among 
IMS NPA were identified those who were prescribed 5 or more medicines at least 
once through October to December in 2009.  
 Univariable logistic regression models were used to calculate odds ratios and 95% 
confidence intervals (CIs) for the relationship between each variables and 
polypharmacy.  
 
2.6 Statistical power and sample size 
 Given the sample size of 460 patients, the proposed study was expected to have 
80% statistical power to detect the statistical significance of odds ratio (ORs) of 
approximately 1.3 for each standard deviation increase in the mean value of a given 
variable (e.g., age), using an alpha of 0.05, one-tailed test and assuming 35% of 
patients would have met the outcome (i.e., classified as "polypharmacy") (Hsieh, 
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1989).  
 
2.7 Statistical analysis procedure 
  A multiple logistic regression model with stepwise selection was applied to identify 
the independent predictors of polypharmacy (dependent variable). Nine types of 
information were eligible for entry as independent predictors of polypharmacy: age, 
sex (females – referent group), the number of visits to medical institutes, severity of 
comorbidity (measured by the Charlson Comorbidity Index [CCI]), and drug category. 
35 categories at 2-digit level (Box 2-1) were adapted for drug information to 
descriptive analysis and logistic regression model. If no participant of either 
non-polypharmacy or polypharmacy group used a drug of a certain category, that 
category was excluded from statistics. One of two variables was to be excluded, if 
strongly correlated coefficient was identified. 
 Self-reported medical conditions such as hypertension and bone disorder were 
separately tested. ORs and 95% CIs were calculated as well, although each disease 
was not entered into the model. 
  Goodness of fit of logistic regression models is weakened when an unrelated 
variable is entered as an explanatory variable and when only a small number of 
observations is available. Therefore, to select variables to be entered into the models, 
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correlation coefficients of all variables were reviewed.  
  The entry criterion for the stepwise model was a p-value of 0.20; the stay criterion 
was 0.20 (Ohashi and Hamada 1995:p145). The final regression model was 
evaluated for goodness-of-fit according to the Hosmer-Lemeshow statistic 
(Lemeshow and Hosmer, 1982). SAS version 9.2 was used for analysis. 
 
Box 2-1  2-digit classification of drugs, defined by the MHLW 
   11  Central nervous system agents 
   12  Peripheral nervous system agents 
   13  Sensory organ agents 
   19  Other agents affecting nervous system and sensory organs 
   21  Cardiovascular agents 
   22  Respiratory organ agents 
   23  Digestive organ agents 
   24  Hormones 
   25  Urogenital and anal organ agents 
   29  Other agents affecting individual organs 
   31  Vitamins 
   32  Nutrients, tonics 
   33  Blood and body fluid agents 
   34  Dialysis agents 
   39  Other agents affecting metabolism 
   41  Cellular function activating agents 
   42  Antineoplastics 
   43  Radioactive drugs 
   44  Allergic agents 
   49  Other agents affecting cellular function 
   51  Crude drugs 
   52  Traditional Chinese medicines 
   59  Other crude drugs and Chinese medicine formulations 
   61  Antibiotics 
   62  Chemotherapeutics 
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   63  Biological preparations 
   64  Parasitics (systemic) 
   69  Other agents against pathogenic organisms and parasites 
   71  Dispensing medicines 
   72  Intracorporeal diagnostic agents 
   73  Public health agents 
   74  Extracorporeal diagnostic agents 
   79  Other agents not mainly for therapeutic purpose 
   81  Alkaloidal narcotics 
   82  Non-alkaloidal narcotics 
   89  Other narcotics 
 
2.8 Drug utilisation from patient safety perspective 
 Systematic evaluation of possible safety issues was completed with technical 
support from System Yoshii, Co. Ltd. The analysis has been conducted on the 
prescription drugs encoded with MHLW drug classifcation (N=3298) and the 
substances of OTC available for encoded with MHLW drug classification. They 
picked up potential issues on duplicate drugs, contraindications and interactions by 
use of their original system software based on regulated product information valid as 
of December 2009 (Kusama, 2010). The detected issues did not indicate whether or 
not a medication regimen was medically acceptable. In this study, probability of 
safety issues is tested by chi-square test between polypharmacy and 
non-polypharmacy groups to generate OR and 95%CI. 
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2.9 Ethical approval 
 All data from the participating pharmacies for Hiroshima Brown Bag Programme 
were anonymous ,and then integrated by the research group of University of Tokyo 
and accredited by Hiroshima Pharmaceutical Association and Regional Health Care 
Council of Hiroshima Prefecture. The Brown Bag Programme was originally 
reviewed by the ethical committee of the University of Tokyo. 
Medicines claim data were anonymous by health insurance organizations before 
providing data to IMS Japan, K.K., and therefore IMS data did not contain any 
identifiable information of patients and doctors. 
This research protocol was reviewed by the Ethics Committee of the University of 
Liverpool (Appendix 9).  
 
3 Results of analysis 
3.1 Study population 
Demographics 
452 elderly persons out of 530 participants of the Brown Bag Programme were met 
with inclusion criteria of this study.  
 Elderly people in the community of Hiroshima consumed a median of 7 drugs and 
ranged from one to 24 including OTC drugs.  
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The median age of study participants was 76 years and 66.2% were female. Based 
on self-reported comorbidities, the most common disease was hypertension (60.8%), 
and some others were observed; hyperlipidemia (34.7%), gastric abnormal (24.1%) 
and eye disorder (20.3%), heart failure (19.5%) (Table 3-1, Appendix 7-1). 78.3% 
(123/157) of patients with Hyperlipidemia were female, 64.4%(177/275) with 
hypertension, 91.7%(77/84) with osteoporosis respectively.  
 
Table 3-1 Background of the study population 
 This study 
Aim To assess prescribing patterns and to determine predictors of 
polypharmacy 
Country Japan 
Subjects ≥65 , male and female 
Size of population 452 
Setting Community pharmacy 
Age  Median 76 (65-97) 
Sex Male 153 (33.8%) Female 299 (66.2%)  
Polypharmacy ≥5 prescriptions and OTCs, 69.8% 
≥5 prescriptions, 65.8% 
Sampling Voluntary participants 
Number of diagnosis  
None≤ ≤2 
3 or 4 
5≤ 
CCI  
Zero 
1  
2≤ 
Median 3, Range 0-8 
202 
183 
63 
Median 1, Range 0-9 
186 
173 
114 
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Common disease(%) Hypertension 60.8% 
Hyperlipidemia 34.7 % 
Gastric abnormal 24.1%  
Eye disorder  20.3% 
Heart failure 19.5% 
Number of drugs  Median 7, Ragne 1-24 (including OTCs) 
Common drugs (%) Cardiovascular 78.4% 
Digestive organ 57.9% 
Central nervous system 56.3% 
Metabolism 35.1% 
Blood and body fluid agents 29.6% 
Vitamins 28.7% 
Statistical Method Multiple variable logistic regression model 
 
3.2 Univariate analysis 
Number of drugs used per person 
 Of the 452 elderly persons included in the analysis, 315 (69.8%) participants met 
the definition for polypharmacy (65.8% when only prescription medications were 
considered). A median of number of drugs was 7 (range:1-24) overall, 3 (range:1-4) 
among the non-polypharmacy group and 8 (range:5-24) among the polypharmacy 
group. 
The maximum number of medicines used per person was 24, that is 22 prescription 
and 2 OTC drugs (ParticipantID 243). There were 3 participants who did not report 
any prescription drug, and they were in the non-polyphrmacy group (ParticipantID 
69, 432, 491). Number of drugs per person was not normally distributed.  
 The median of number of drugs among polypharmacy group was 8 when including 
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OTC drugs. Excluding OTC drugs, the participants with five and more prescription 
drugs were 297(65.8%), and the median of number of drugs was 9.   
Medication class 
 The total number of recorded medicines was 3322 among 452 participants of the 
Brown Bag Programme, including 270 OTC drugs (Appendix 7-2). The 3052 
prescription drugs were recorded, which consisted of 91.9% of all medicinal product 
records. Three participants reported OTC drugs only. Prescription drugs were 
identified in 70 out of 139 drug categories at the third level of MHLW classification, 20 
out of 38 categories at the second level. 115 patients used drugs that has not been 
encoded such as plasters, eyedrops, and 170 patients used certain kinds of OTC 
drugs.  
 „Antihypertensives‟ was the most commonly used (N=202, 44.7%), and „Peptic ulser 
agents‟ were (N=193, 42.7%), followed by „Vasodilators‟ (N=193, 44.2%) and 
„Hyperlipidemia agents‟ (N=163, 37.3%). 23 drug categories were not found among 
the sub-group of non-polypharmacy at the 3-digit classification level (Appendix 7-3). 
Notably, 41 participants used „Antidiarrheals, intestinal regulators‟ and 19 
participants used „Multivitamin preparations‟ among the polypharmacy group, while 
no one took among the non-polypharmacy group. In turn, a drug class that has no 
patient in non-polypharmacy group was considered as strong predictor of 
36 
polypharmacy.  
 The highest prevalence of drug class among the study cohort was Cardiovascular 
agents (78%), Digestive organ agents (57%) and Central nervous system agents 
(56%)(Appendix 7-2), when categorised at the 2-digit level of the therapeutic 
classification system unique to Japan (Appendix 7-2). At the second level of the 
MHLW drug code, no drugs of 18 categories were identified among the study cohort, 
and they were excluded from the regression model. More than one person used a 
drug of any one of 20 categories. In conclusion, 20 drug classes were considered as 
possible independent variables (Table 3-2): Central nervous system agents, 
Peripheral nervous system agents, Sensory organ agents, Cardiovascular agents, 
Respiratory organ agents, Digestive organ agents, Hormones, Urogenital and anal 
organ agents, Other agents affecting individual organs, Vitamins, Nutrients and 
tonics, Blood and body fluid agents, Other agents affecting metabolism, 
Antineoplastics, Allergic agents, Crude drugs, Traditional Chinese medicines, Other 
crude drugs and Chinese medicine formulations, Antibiotics, Chemotherapeutics. 
Most of them showed positive relation to polypharmacy (Table 3-2). 
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Figure 3-1 Flowchart of medicines record available for this study 
 
 
Table 3-2 Frequency and odds ratio of variables  
Drug Category Polypharmacy/Total (%) OR (95%CI) 
P<0.01 
Female 
Age class 
Medical Institute 
CCI  
209/299 
- 
- 
- 
0.6 (0.3-1.2) 
- 
- 
- 
OTC 131/170 (77.1) 1.8 (1.2-2.7) 
11 
12 
13 
218/255 (85.5) 
34/35 (97.1) 
21/24 (87.5) 
6.0 (3.8-9.4) 
16.4 (2.2-121.0) 
3.2 (0.9-10.8) p=0.05 
21 
22 
23 
24 
25 
29 
266/355 (74.9) 
44/48 (91.7) 
233/258 (90.3) 
37/39 (94.9) 
51/58 (87.9) 
2/2 (100) 
2.9 (1.8-4.6) 
5.4 (1.9-15.3) 
12.6 (7.6-20.8) 
9.0 (2.1-37.7) 
3.6 (1.6-8.1) 
- 
31 
32 
33 
39 
115/130 (88.5) 
16/16 (100) 
115/134 (85.6) 
127/159 (79.9) 
4.7 (2.6-8.3) 
6.8 (0.9-51.8) p=0.03 
3.6 (21-6.1) 
2.2 (1.4-3.5) 
42 
44 
7/12 (58.3) 
63/70 (90.0) 
0.6 (02-1.9) p=0.38 
4.6 (2.1-10.4) 
38 
51 
52 
59 
2/2 (100) 
69/79 (87.3) 
1 /1(100) 
- 
3.5 (1.8-7.1) 
- 
61 
62 
NOS 
10/12 (83.3) 
15/17 (88.3) 
106/115 (92.2) 
2.2 (0.5-10.2) p=0.30 
3.4 (0.8-14.9) p=0.09 
7.2 (3.5-14.7) 
11: Central nervous system agents, 12: Peripheral nervous system agents, 13: 
Sensory organ agents, 21: Cardiovascular agents, 22: Respiratory organ agents, 23: 
Digestive organ agents, 24: Hormones, 25: Urogenital and anal organ agents, 29: 
Other agents affecting individual organs, 31: Vitamins, 32: Nutrients, tonics, 33: 
Blood and body fluid agents, 39: Other agents affecting metabolism, 42: 
Antineoplastics, 44: Allergic agents, 51: Crude drugs, 52: Traditional Chinese 
medicines, 59: Other crude drugs and Chinese medicine formulations, 61: Antibiotics, 
62: Chemotherapeutics, NOS: Not otherwise specified 
 
Gender 
The male-female ratio of the study population was not significantly different 
between the non-polypharmacy and polypharmacy groups. The male-female ratio of 
the study population was not significantly different between the non-polypharmacy 
and polypharmacy groups, with 69.7% of females being classified as polypharmacy 
medicine users compared with 72.5% of males. 
Age 
 There did not appear to be an association of polypharmacy with age. The median 
age of the polypharmacy group was slightly higher than the non-polypharmacy 
group (78 vs. 76, p<0.01) (table 3-1). Furthermore, there was no linear trend in 
percent of persons with polypharmacy across age groups (table 3-2).    
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 The average age of non-polypharmacy group was younger than polypharmacy 
group by 2.37 years (Appendiex 7-1), and age was not normally distributed 
(Appendix 7-4). The Kruskul-Wallis test for age distribution between 
non-polypharmacy and polypharmacy was not statistically significant (p=0.22) (Table 
3-2). There was no liner relation in the proportion of polypharmacy between ages 
(Figure 3-2). 
 6 dummy variables for 5-year age classes were developed to explore difference 
between the groups to see the pattern of age distribution comaring with the IMS NPA 
data. There was liner relation between age class and the proportion of polypharmacy 
up to the sub-group of 85 to 90 in the Brown Bag Programme (Figure 3-3). The 
number of participant aged 90+ was twelve only in the Brown Bag Programme, which 
would make statistical analysis weak. These two data source showed similar pattern 
in OR at each age class and gender, showing increase with age class. 
 
Table 3-3 Profile of the study population of Brown Bag Programme 
Brown Bag 
Programme 
Total 
N=452 
Non- 
polypharmacy 
N=137 (%) 
Polypharmacy 
N=315 (%) 
OR (95% CI) 
P value* 
Female 
Male 
299 
153 
95 (31.8) 
42 (27.5) 
204 (68.2) 
111 (72.5) 
0.8 (0.5-1.2) 
p=0.9  
Age range 
median 
65 to 97 
76 
65 to 96 
74 
65 to 97 
78 
P=0.22 † 
Age 65-69 
70-74 
96 
91 
44 (45.8) 
27 (29.7) 
52 (54.2) 
64 (70.3) 
Reference 1.00 
2.0 (1.1-3.7) p=002 
40 
75-79 
80-84 
85-89 
90+ 
119 
99 
35 
12 
33 (27.7) 
24 (24.2) 
5 (14.3) 
4 (33.3) 
86 (72.3) 
75 (75.8) 
30 (85.7) 
8 (66.7) 
2.2 (1.3-3.9) p<0.01 
2.6 (1.4-4.9) p<0.01 
5.1 (1.8-14.2) p<0.01 
1.7 (0.5-6.0) p=0.42 
*chi-square test 
†Kruskal-Wallis Test 
 
Figure 3-2 Proportion of polypharmacy group in each age 
 
 
Figure 3-3 The proportion of polypharmacy in age sub-groups of the Brown Bag 
Programme 
  
 
13	
7	
7	
8	 9	
6	 6	
3	
5	
7	
5	
9	
5	
8	
6	
5	
2	
8	
5	 4	
1	 1	 1	
2	 1	 1	
1	
1	
13	
10	
6	
11	 12	
12	 12	
19	
15	
6	
14	
15	
12	
30	
15	
17	
18	
15	
13	 12	
8	 8	 7	
4	
3	
2	 2	
1	
2	 1	
0%	
10%	
20%	
30%	
40%	
50%	
60%	
70%	
80%	
90%	
100%	
65	 66	 67	 68	 69	 70	 71	 72	 73	 74	 75	 76	 77	 78	 79	 80	 81	 82	 83	 84	 85	 86	 87	 88	 89	 90	 91	 92	 94	 96	 97	
non-polypharmacy	 polypharmacy	
52	
64	 86	 75	
30	
8	
44	
27	 33	 24	
5	
4	
0%	
10%	
20%	
30%	
40%	
50%	
60%	
70%	
80%	
90%	
100%	
65-69	 70-74	 75-79	 80-84	 85-89	 90=<	
Polypharmacy	 non-polypharmacy	
41 
Disease condition 
Univariate logistic regression was applied to each disease as well to estimate the 
significance relating to polypharmacy. Significant difference was not found among 
Hyperlipidaemia, diabetes and eye disorder and so on. Contrarily, hypertension, 
heart failure, gastric abnormal, ospeoporosis, and backache indicated association 
with polypharmacy (Appendix 7-1).  
 About 80% of the study population was visiting one or two medical institutitons, 
however, that percentage was different between non-polypharmacy and 
polypharmacy groups (Table 3-3).  
 The median of CCI was 1 (range: 0-9), and the proportion of participants with zero 
score of this index was 36.6%. The median of self-reported medical conditions was 
was 3 (range:0-8). Number of disease, CCI, and number of visiting medical facilities 
were not normally distributed, and then applied non-parametric test. CCI shows 
significant difference between non-polypharmacy and polypharmacy (p<0.01). As 
generally presumed, number of disease and number of visiting medical facilities were 
also correlated with polypharmacy. 
 
Table 3-4 Univariate analysis on health status of patient with/without 
polypharmacy 
 Total  
(N, %) 
Non- 
polypharmacy 
Polypharmacy 
(N, %) 
P value 
OR (95% CI) 
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N=452 (N %) N=137 N=315 
Number of visiting 
medical institute 
  Range 
  Median 
     1 
     2≤ 
     Unknown 
 
 
1 to 6 
2 
171  
249  
32 
 
 
1 to 5 
1 
77 (45.0) 
48 (19.3) 
12 
 
 
1 to 6 
2 
94 (55.0) 
201 (76.7) 
20 
 
 
p<0.01† 
 
1.00 
3.4 (2.2-5.3) p<0.01* 
 
CCI 
   Range 
   Median 
   0 
   1≤ 
 
0 to 9 
1 
166  
287  
 
0 to 7 
0 
79 (47.6) 
58 (20.3) 
 
0 to 9 
1 
87 (52.4) 
229 (79.7) 
 
P<0.01† 
 
1.0 
3.6 (2.3-5.4) p<0.01* 
†Kruskal-Wallis Test 
*Chi-square test 
CCI: Charlson Comorbidity Index 
 
3.3 Predictors of polypharmacy and logistic regression model 
Variables eligible for entering 
Although multicolinearity is known issue in logisti regression analysis, this is not 
much concern in stepwise selection. Considering all discussed above, the 
independent variables were identified; gender (female), age, number of visiting 
medical facility, Charlson comorbidity index, and 20 drug classifications as defined in 
the section 3-1. Age was classified into six age classes with 5-year range. Number of 
visiting medical facilities and CCI were not normally distributed and grouped; two 
classes (1 and 2+ ) of medical facilities; two classes (0 and 1+) of CCI. These classes 
were divided at the median.  
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Outcome of Logistic regression model 
  A logistic regression analysis with stepwise selection model was applied to explore 
predictors of polypharmacy. SAS Programme is shown in Appendix 7-10. The 
significance level for entering an effect and removing it was set 0.20. „Age class‟, 
„number of medical facilities‟ were not significant in score chi-square test of residuals 
(p>0.2) and they were removed from the model. Likewise, 7 drug categories were 
removed, then OTC and 12 drug categories (Central nervous system agents, 
Peripheral nervous system agents, Cardiovascular agents, Digestive organ agents, 
Hormones, Urogenital and anal organ agents, Vitamins, Nutrients, tonics, Blood and 
body fluid agents, Other agents affecting metabolism, Allergic agents, Traditional 
Chinese medicines) were remained. 
The probability of each variable was less than 0.05 except two variables („Peripheral 
nervous system agents‟ and „Nutrients, tonics‟). „Digestive organ agents‟ showed 
high score chi-square over 100 (p<0.01). CCI was entered into the logistic regression 
model, and the result showed that a patient with CCI≥1 had 2 times higher possiblity 
of polypharmacy compared to a patient with CCI=0 (p=0.08). There is no evidence of 
a lack of fit in the selected model, evaluated by Hosmer-Lemeshow test 
(chi-square=3.8 p=0.88).  
Accuracy of prediction by the model 
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 It is important for predictive modeling to score dataset. In this case, a new data set 
to be fit to the model was not available, and posterior probabilities were reviewed to 
validate a goodness of fit. The contingency table with values observed and estimated 
by scoring dataset was developed (Appendix 7-11), and the performance of the 
model was described; positive predictive value:93%, negative predictive value: 
78.1%, sensitivity:90.7%, specificity: 83.0%.  
Outliners effect 
 The effect of outliners was evaluated by use of Cook‟s distance. Of 452 
observations entered to the model, two observations were over 1.0 of cook‟s 
distance scale (ParticipantID=272, 283) (Appendix 7-12). Two obeservations were 
removed to see changes in coefficients of the regression model before and after 
taking outliners out. The new dataset of 450 observations was applied for logistic 
regression model. Female, CCI and „Nutrients, tonics‟ were removed from the model. 
 
Table 3-5 Coefficients of logistic regression model and corresponding odds ratio 
Variable Odds Ratio (95% CI) P value 
Gender (Female) 0.6 (0.3-1.2) P=0.12 
CCI 1+ vs 0 1.9 (0.9-3.9) P=0.08 
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Drug class§  
11 
12 
21 
23 
24 
25 
31 
32 
33 
39 
44 
52 
otc 
 
9.4 (4.4-20.4) 
14.2 (0.6-336.2) 
10.5 (4.3-25.5) 
14.9 (6.5-34.2) 
12.4 (1.5-105.1) 
2.8 (0.8-9.7) 
3.4 (1.4-8.6) 
7.4 (0.7-81.6) 
4.2 (1.8-9.7) 
7.3 (3.0-17.8) 
10.1 (2.6-39.2) 
7.2 (2.3-22.8) 
3.9 (1.8-8.3) 
 
P<0.01 
P=0.10 
P<0.01 
P<0.01 
P=0.02 
P=0.10 
P<0.01 
P=0.10 
P<0.01 
P<0.01 
P<0.01 
P<0.01 
P<0.01 
N=420, Hosmer and Lemeshow test: 3.8 P=0.88 
* CCI: Charlson Comorbidigy Index, scored 0, 1, 2, 3+ 
§11: Central nervous system agents, 12: Peripheral nervous system agents, 21: 
Cardiovascular agents, 23: Digestive organ agents, 24: Hormones, 25: Urogenital 
and anal organ agents, 31: Vitamins, 32: Nutrients, tonics, 33: Blood and body fluid 
agents, 39: Other agents affecting metabolism, 44: Allergic agents, 52: Traditional 
Chinese medicines. 
 
3.4 Potential Risk of interactions and duplications 
Supported by System Yoshii, Co.Ltd., I examined the proportion of those who has 
potential risk of interaction, contraindication and duplication based on the information 
provided in the regulated package insert of each product. OTC ingredients were 
encoded into 7-digit number of the MHLW code representing ingredient and category, 
since there is no stractured package information available for risk detection. All 
ingredients of reported drugs were analysed systematically. Polypharmacy group 
had 14 times higher risk than non-polypharmacy group (chisquare 133.4 p<0.05, 
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Risk Ratio 14.0, 95%CI 8.5-22.8). 
Table 3-6 Risk Ratio of potential issues relating to interaction, duplication and 
contraindication 
 One or more potential 
risk observed 
Nothing observed 
 
Non-polypharmacy 
N=137 
49 
35.8% 
88 
64.2% 
Polypharmacy 
N=315 
279 
88.6% 
36 
11.4% 
 328 124 
 
3.5 Generalizability of the study population 
Based on IMS NPA data, the number of drugs per visit per person was 4.4 in total, 
and the median was 3. Polypharmacy was found 38% of the patients, which was 
quite different than the Brown Bag Programme. the avarage and median of number 
of drugs among polypharmacy group was 8.2 and 7 respectively. 
The male-female ratio of the IMS NPA data was fitted to the Brown Bag Programme. 
Medication situation presented by IMS NPA 
 Simirarily, the frequency of drugs categorised into ATC at the first level was 
accumulated from IMS NPA of 22470 patients. IMS data included 8617 patients with 
polypharmacy out of 22470 patients in total (38.3%). IMS NPA data had 79032 
pharmacy-visit records of 22470 patients, and showed that 4.4 (SD=3.7, Median:3) 
drugs were despenced per person per dispensing on average. Approximately 80% 
patients of polypharmacy group took any kinds of drugs for “Alimentary tract and 
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metabolism” and/or “Cardiovascular system”, while about 30% for 
non-polypharmacy group. This result was similar to the result of the Brown Bag 
Programme. More non-polypharmacy patients took drugs working on nerves system 
rather than patients with polypharmacy. 
 
Table 3-7 Number of patietns recorded in IMS data by ATC drug groups  
ATC 
Primary 
level 
Total 
N=22470 
Non- 
polypharmacy 
N=13853 (%) 
Polypharmacy 
 N=8617 (%) 
OR (95%CI) 
P<0.001 
A 10770 (47.9) 3875 (27.97) 6895 (80.02) 10.3 (9.7-11.0) 
B 4279 (19.0) 1117 (8.0) 3162 (26.7) 6.6 (6.1-7.1) 
C 11036 (15.0) 4288 (31.0) 6748 (78.3) 8.1 (7.6-8.6) 
D 5784 (11.3) 3458 (25.0) 2326 (27.0) 1.1 (1.0-1.2) 
G 1453 (0.7) 399 (2.9) 1054 (12.2) 4.7 (5.2-5.3) 
J 3239 (14.4) 1388 (10.0) 1851 (21.4) 2.5 (2.3-2.6) 
M 7445 (33.1) 2883 (20.8) 4562 (52.9) 4.3 (4.0-4.5) 
N 5300 (23.6) 1521 (61.7) 3779 (43.9) 6.3 (5.9-6.8) 
R 5451 (24.3) 2028 (14.6) 3423 (39.7) 3.8 (3.6-4.0) 
S 3871 (17.2) 2827 (20.4) 1044 (12.1) 0.5 (0.5-0.6) 
V 2629 (11.7) 801 (5.8) 1028 (21.2) 4.4 (4.0-4.8) 
A: Alimentary tract and metabolism, B: Blood and blood forming organs, C: 
Cardiovascular system, D: Dermatologicals, G: Genito urinary system and sex 
hormones, H: Systemic hormonal preparations, excl. sex hormones and insulins, J: 
Antiinfectives for systemic use, L: Antineoplastic and immunemodulating agents, M: 
Musculo-skeletal system, N: Nervous system, P: Antiparasitic products, insecticides 
and repellents, R: Respiratory system, S: Sensory organs, V: Various 
 
 
Table 3-8 Profile of the IMS NPA data 
IMS NPA Total  
N=22470 (%) 
Non-polypharmacy 
N=13853 (%) 
Polypharmacy 
N= 8617 (%) 
OR(95% CI) 
P value 
Female 
Male 
13411 (59.68) 
9059 (40.32) 
8285 (59.8) 
5568 (40.2) 
5126 (59.5) 
3491 (40.5) 
1.0 (0.96-1.07) 
p=0.6 
Age 65-69 5942 (26.44) 4184 (30.2) 1758 (20.4) Reference 1.0 
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70-74 
75-79 
80-84 
85-89 
90+ 
5316 (23.66) 
4721 (21.01) 
3567 (15.87) 
1700 (7.57) 
1224 (5.45) 
3520 (25.4) 
2793 (20.2) 
1863 (13.5) 
887 (6.4) 
606 (4.4) 
1796 (20.8) 
1928 (22.4) 
1704 (21.0) 
775 (9.0) 
656 (7.6) 
1.2 (1.1-1.3) 
1.6 (1.5-1.8) 
2.2 (2.0-2.4) 
2.1 (1.9-2.3) 
2.6 (1.9-2.9) 
p<0.01 
 
 
Figure 3-4 The proportion of polypharmacy in age sub-groups 
 
 
4 Discussion 
4.1 Background and setting 
  Aging populations are a challenge worldwide; the healthcare needs of elderly 
people place an increased burden on healthcare systems (WHO, n.d.a). Long-term 
use of medicines to treat chronic disease is one of the main concerns associated with 
medication usage in elderly patients. Other medication-related problems include 
pharmacokinetic and pharmacodynamic changes (ibid) and the use of concurrent 
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medications for comorbidities (Hajjar etal. 2007; Masoodi, 2008). Although 
„polypharmacy‟ and „the elderly‟ have been widely studied worldwide, including 
Japan, most of the published literature comprises descriptive reports in the clinical 
setting or discussions on factors likely to contribute to polypharmacy. However few 
studies have focused on safety problems such as ADRs in relationship to 
polypharmacy. While we found 4 studies reporting predictors of 
polypharmacy(Junius-Walker et al. 2007; Rozenfeld et al. 2008; Harugeri, et al. 
2010; Nobili et al. 2011), no research has been conducted on the elderly Japanese 
population. Thus, this was the focus of the present study.  
In this study, secondary data from the Brown Bag Programme was used to describe 
the patterns and potential safety issues related to prescription and OTC drug use and 
to explore the predictors of polypharmacy.  
 
4.2 Demographics of the study population 
Gender 
In this study, female participants (66%) seemed to be overrrepresented. In 2009, 
57% of the elderly population in Japan–that is, people aged 65 years and over–were 
female (Japan Cabinet, 2010), while IMS data showed that the proportion of female 
patients among patients visiting pharmacies in Hiroshima from October 2009 to 
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December 2009 was 58%. One German study, which adopted a similar approach for 
participant selection as the Brown Bag Programme, showed that there were twice as 
many female participants as males (Junius-Walker et al. 2007). A voluntary approach 
of the Brown Bag Programme may have increased the number of female participants, 
e.g., 28% of male vs 54% of female vs 19% of unkown in the UK study (Nathan et al. 
1999), and 44% of male vs 66% of female in this study.  
 Some studies have indicated that gender was not associated with polypharmacy 
(Junius-Walker et al. 2007; Harugeri, et al. 2010; Nobili et al. 2011). However, this 
study demonstrated that being female was associated with polypharmacy. Among 
female participants, the prevalence of osteoporosis and hyperlipidemia was 
significantly higher than that among the male participants. However, it is not 
appropriate to make conclusions about the association between gender and 
polypharmacy at this time.  
Age 
In this study, 58.7% of the participants were aged 75 years old and above. The 
average age was 76.1 years, and median age was 76 years. The number of eldery 
persons whithin the IMS NPA data was decreased as aged, while the number of 
participants aged 75–79 years was the largest in the Brown Bag Programme. In 
earlier studies on polypharmacy in elderly populations, there were various age 
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distributions: 76.3-79.4 years on average (Junius-Walker et al, 2006; Nobili et al., 
2011) and a median of 66 with the rage 60-95 (Harugeri et al., 2010), and a mean of 
81 years with the range of 75-96 (Jrykka et al, 2009a and 2009b).  
 In this study, the logistic regression model did not show age to be a predictor of 
polypharmacy, but univariate analysis showed an odds ratio of 2.0–5.0 in each age 
class. Conversely, Rozenfeld et al. (2008) reported that age had a positive 
association with polypharmacy when patients were placed in the following age 
groups: 60–69, 70–79, and >80 years. Meanwhile, Nobili et al. (2011) suggested that 
age of 85 years or above was significantly associated with polypharmacy.  
 Age is a known determinant of health (Naidoo and Willis 2000), and increased age 
can lead to the use of multiple medications to treat ill health. However, age 
distribution and relationship with polypharmacy can vary from region to region, and 
among study settings, e.g. community or hospital settings. The results of 
population-based studies may need to be adjusted for age to help evaluate 
polypharmacy more precisely. 
Comorbidity 
Hypertension (61%), gastric abnormalities (24%), heart failure (19%), and 
osteoporosis (19%) were the major diseases observed in the Brown Bag Programme. 
In the polypharmacy and non-polypharmacy groups, statistically significant 
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differences were found in the incidence of each disease. The prevalence of patients 
with hyperlipidemia was equal in both groups. Diabetes, eye disorders (difficulty in 
seeing), and respiratory disorders such as chronic obstructive pulmonary disease 
(COPD) and breathlessness were less common in this study, compared with studies 
conducted in other countries. We assumed that the lower prevalence of self-reported 
respiratory disease might be the result of a lack of awareness of airflow obstruction 
(Fukuchi eta l. 2004) by the participants of the Brown Bag Programme. Thus, the 
concurrent diseases that the study subjects could report were unique to this study. 
Furthermore, when multivariable analysis was applied for drug categories, 
pharmacotherapy for respiratory disorder was excluded; thus, it was not considered 
a predictor of polypharmacy. However, other studies have found respiratory disorder 
to be a predictor of polypharmacy (Junius-Waker et al. 2007; Nobili et al. 2011).  
Charlson Comorbidity Index vs Chronic disease score 
CCI was applied to summarise an individual‟s awareness of concurrent underlying 
diseases. The CCI was devised by Charlson et al. (1987) as a method to classify 
comorbid conditions associated with the risk of mortality. The index can be used to 
evaluate the seriousness of comorbid diseases. Similarly, the Chronic Disease Score 
(CDS) (von Korff et al. 1992) was considered. The CDS is calculated from 
prescription information, and it is used to assess chronic diseases. The report by 
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McGrerar et al. (2005) indicated that CCI and CDS were compatible to some extent. 
Other studies have evaluated individual diseases as independent variables 
(Junius-Walker et al. 2007; Rozenfeld et al. 2008; Harugeri et al. 2010; Nobili et al. 
2011). There are no published studies for comparison with this study in terms of our 
results on the association between CCI and polypharmacy. Further research is 
necessary on how to evaluate health conditions (e.g. severity and quality of life) and 
utilize such an index. Application of CCI in the analysis of drug use among the elderly 
was a challenge. Its validity and usefulness now need to be confirmed.  
 
4.3 Drug use pattern  
Definition of Polypharmacy 
Polypharmacy in elderly populations has been discussed in the literature for over 30 
years, and many researchers have investigated drug use pattern in various clinical 
settings, e.g. ambulatory practice, long-term institutions, and general practice 
(German 1989). However, there is a lack of published population-based studies on 
polypharmacy among elderly community-dwelling people in Japan. For the purpose 
of this study, „polypharmacy‟ was defined as the use of 5 or more drugs including 
OTC drugs. However, it should be noted that polypharmacy has been defined 
differently in different clinical setting, and there is no common definition.(Fulton and 
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Allen, 2005) Previous definitions have included „concurrent use of 2 or more drugs‟ 
and „use of 4 or more medications‟. However, the most common definition in research 
on predictors of polypharmacy seems to be „the use of 5 or more prescription drugs‟ 
(Junius-Walker et al. 2007; Rozenfeld et al. 2008; Harugeri, et al. 2010; Nobili et al. 
2011)It is important to note that these earlier studies did not consider OTC drug use, 
which is common among patients living in the community). Because of the varying 
definitions of polypharmacy used in earlier studies, it is quite difficult to interpret 
differences between the results of this study and those of other studies.  
High drug consumption among the elderly in Japan 
Among the elderly participants of the Brown Bag Programme, a median of 7 
prescription and OTC drugs were consumed. A total of 65.8% of the participants 
consumed 5 or more medicines, excluding OTC drugs, with the maximum being 24 
by 1 individual (22 prescription and 2 OTC drugs). These results were higher than 
those of other studies; for example, the proportion of elderly patients with 5 or more 
prescriptions was about 27% in a German community (Junius-Walker et al. 2007) 
and 37% in a Brazilian community (Rozenfedd et al. 2008). 
Based on the IMS NPA data, 4.4 prescription drugs were prescribed on average, 
and 38% of the cohort were using multiple medications. The IMS NPA data indicated 
that the proportion of polypharmacy and the average number of medications used 
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were both significantly lower than those of eldery participants of the Brown Bag 
Programme, and they were slightly higher than the findings of Junius-Walker et al. 
(2008) and Rozenfeld et al. (2010), both of which looked based on outpatient data. 
Taken together, this suggests that elderly community-dwelling Japanese people are 
prone to polypharmacy. However, as the participants of the Brown Bag Programme 
were originally invited to participate in a medication use review, those who were 
using concomitant medications were unlikely to take part in the programme. It was 
suggested that elderly Japanese people in the community consuemd such large 
quantities of drugs that „5 and more drugs‟ as a definition of polypharmacy was 
appropriate for this group.  
Prescription drug classes 
This study with the use of the data from the Brown Bag Programme found that drugs 
for hypertension, vasodilators, hyperlipidemia, and peptic ulcer were prescribed. The 
prevalence of the use of these drugs was similar to that of other recent studies to 
some extent (Table 4-1). Common classifications of medicines prescribed for the 
elderly in the literature were those acting on the cardiovascular system and the 
alimentary tract, those for cerebrovascular disease, and those for the central nervous 
system (Table1-1). In addition, elderly people consumed analgesics and vitamins 
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(Martin and Coleman, 2007). Thus, this study may reflect the general characteristics 
of medicine use among the elderly.  
One study conducted in a Japanese hospital showed that, in the cardiovascular 
internal medicine ward, there was a possible association between age and number of 
concurrent medication. However, the study did not find such an association in the 
respiratory ward and the digestive tract internal medicine ward (Yasuhara, 1980). It is 
likely that cardiovascular diseases could result in various accompanying symptoms 
with age so that elderly patients would need multiple medicines for treatment 
(Yasuhara, 1980). The Brown Bag Program confirmed that patients using 
cardiovascular drugs had a higher risk of polypharmacy (OR 2.9, 95%CI 1.8–4.6), as 
seen in the preceding studies. Moreover, rug use for respiratory diseases had no 
significant relation to polypharmacy, according to the results of univariate and logistic 
regression analyses, which was different from the findings of other studies. 
In contrast to other published studies, ATC has not been applied in this study for drug 
classification; however, use of the Japanese unique drug classification system 
suggested that the overall profile of prescription use in elderly people appeared 
similar to other studies (Rozenfeld et al. 2008; Harugeri et al., 2010; Nobili et al, 
2011). 
Clinical needs of prescription drugs 
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From the clinical point of view, the pharmacotherapy of multiple medications is 
necessary for treatment, and elderly people more often suffer from chronic diseases 
that result in a long-term care at home. Therefore, it is essential to evaluate the 
benefit-to-risk of drug therapy for each patient to minimise the risks associated with 
polypharmacy (Planton and Edlund, 2010). However, it is also important to 
periodically monitor and assess medication used to „optimise‟ individual 
pharmacotherapy without refraining from the administration of necessary 
prescription medicines. Bellentine (2008) also noted that the balance between 
benefit and risk of polypharmacy in elderly populations needs to be monitored 
consistently. Moreover, medication use review (MUR) by pharmacists, which will be 
discussed later, would help rationalise medication use in terms of improving quality of 
life for aging populations. 
OTC drugs 
In this study, „polypharmacy‟ was defined as „use of 5 or more medicines including 
OTC drugs‟. OTC drug use was 38% for the elderly participants, which was slightly 
lower than the result (45%) reported by Junius-Walker, (2007) which studied OTC 
drug use but did not include OTC drugs in its statistical analysis.  
Two factors should be considered when discussing OTC drug use pattern in Japan. 
First, different patterns of OTC drug use could be the result of differences in 
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pharmaceutical policy between countries. In Japan, a new regulation was adopted in 
2009, which relaxed the rulse for selling OTC drugs at drugstores in terms of 
licensing salespersons, while it was accompaniesd by a requirement for a 
consultation when selling a product listed as a high-risk OTC drug by the MHLW 
(MHLW, 2009d). As this new regulation is expected to promote self-medication, 
Japanese people may consume more OTC drugs in the future. Therefore, monitoring 
drug use patterns, including OTC drug use, could become more significant for aged 
people who are vulnerable to risks associated with the use of multiple medications.  
The other factor to consider is our method for obtaining information on OTC drug use. 
In this study, OTC drug information was self-reported by participants. This was the 
only possible approach in Japan because OTC products are available from 
drugstores and may be purchased for household stockpiling or for other family 
members. However, self-reported information can be biased. In fact, it has been said 
that home doctors do not know the overall profile of OTC drugs consumed by their 
patients (Junius-Walker 2006).  
 
4.4 Predictors of polypharmacy 
Age and gender 
While the positive association between increasing use of medicines and disease or 
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age was expected before analysis, the results of this study provided important details 
that could help identify possible predictors of polypharmacy. In some polypharmacy 
studies (Jyrkkå et al.2009a; Jyrkkå et al. 2009b), being female was found to be 
associated with polypharmacy, while in both this study and others, being female was 
not statistically significant (Junius-Walker et al. 2007; Harugeri, et al. 2010; Nobili et 
al. 2011). It is estimated that an increase in drug use of about 0.5 drugs is seen every 
10 years among Japanese inpatients (Yasuhara, 1980), and some studies stressed 
that age was an expected predictor of polypharmacy (Nobili, 2011; Jyrkkå et 
al.2009a; Jyrkkå et al. 2009b). Conversely, one study showed that the number of 
drugs per disease does not depend on patient age (Akishita 1994). In this study and 
the study by Harugeri (Harugeri, 2010), ti was found that age was not significantly 
associated with polypahrmacy. Therefore, age and gender are controversial potential 
predictors of polypharmacy.  
Comorbid condition and visit to medical facilities 
Univariate analysis demonstrated that some diseases showed statistically significant 
association with polypharmacy (i.e. hypertension, heart failure, gastric abnormalities, 
osteoporosis, arthritis, backache, and allergy; OR > 2, p < 0.05). As aging could be a 
factor leading to accumulation of chronic conditions that require long-term 
pharmacotherapy, this study found that hypertension was likely to be the disease 
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most significantly associated with polypharmacy, which is similar to the results of 
other studies. Respiratory disease was not significantly related to polypharmacy.  
CCI represents severity of comorbidities, and was thus entered into our logistic 
regression model. About 36.7% of the participants had a CCI score of zero. The 
logistic regression model also revealed a that a CCI score of 1 or more had a 
statistically significant positive association with polypharmacy compared with a score 
of zero. Thus, the total number of diseases and conditions in a patient should be 
monitored more closely than the number of medical facilities they visit. However, 
there are no published studies to help compare the effects of CCI. Harugeri (2010) 
stated that polypharmacy would be increased by 1.5 times in the sub-group of 
patients with 3 or more diagnosed diseases compared with the sub-group of 1 or 2 
diagnoses. Moreover, the serious conditions in the elderly, represented by CCI in this 
study, may require the use of more medicines for relieving symptoms as well as 
treating other diseases. 
Drug category 
Our analysis determined OTC and 12 other drug classes to be predictors of 
polypharmacy; these were central nervous system agents, peripheral nervous 
system agents, cardiovascular agents, digestive organ agents, hormones, urogenital 
and anal organ agents, vitamins, nutrients, tonics, blood and body fluid agents, other 
61 
agents affecting metabolism, anti-allergic agents, and traditional Chinese medicines. 
There are no published studies reviewing drug categories as independent variables 
for polypharamacy, while drug use patterns were briefly mentioned. As discussed 
above, this result reflects the disease profiles of the elderly and the characteristics of 
the regimen for cardiovascular diseases. Drugs for respiratory diseases were not 
identified as a predictor of polypharmacy, which was different from earlier studies 
(Table 1-1, Jyrkka et al. 2006).  
Based on descriptive analysis, antidiarrheals, intestinal regulators, and „multivitamin 
preparations were likely to be strong predictors of polypharmacy at the third level of 
drug classification. „Digestive organ agents‟ and „vitamins‟, upper classes (at the 
level of 2-digit drug class) of those mentioned above, were found to be significant 
association with polypharmacy by both univariate and multivariate analysis. A high 
odds ratio for „peripheral nervous system agents‟ was found in univariate analysis; 
however, no clear relationship with drug class was observed when adjusted by 
covariate analysis.  
This study included OTC drug use as an independent variable in logistic regression 
analysis, and it was found to be a predictor of polypharmacy. The finding that OTC 
drug use is a predictor of polypharmacy means that the use of such drugs should be 
monitored effectively to ensure positive healthcare outcomes. 
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4.5 Strength and limitations of this study 
Study population 
This study focused on participants of the Brown Bag Programme in Hiroshima. The 
generalisability of the study cohort may be questionable in terms of age distribution 
and male-female ratio, and should be carefully interpreted, as there was discrepancy 
between the Brown Bag Programme and the IMS NPA. The American study shows 
that the consistency of the Brown Bag Programme data and pharmacy records was 
high but needed further consideration when it came to age, health status, and types 
of medication used (Caski et al. 2006). However, there is a lack of information on this 
point in Japan. 
Medication use review  
The Brown Bag Programme, which „can provide a useful snapshot of the patient‟s 
current medication use‟ (Steinman and Hanlon, 2010), is recognised as part of MUR 
in the UK, and is recommended by the National Health Service (NHS) to their 
pharmacies (Department of Health, 2005; NHS 2010). The form of MUR in the UK 
(NHS, n.d.) looks simpler than the one used in the Brown Bag Programme in 
Hiroshima, Japan. The NHS form has only 5 questions on medicine taking behavior 
of patients. Moreover, the feasiblity of the forms presented in Appendix 1 and 2 has 
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not yet been evaluated.  
However, the most essential point is to ensure that the medication regimen is 
appropriate for the patient. In terms of improving medicine use in Japan, MUR could 
be an effective and safe approach; it is individualised and could improve patients' 
quality of life (Planton and Edlund, 2010). While medication review at the time of 
dispensing medicine is recognised as the pharmacist‟s role in Japan, the need for the 
clinical service of MUR is not well recognised and is not sponsored by national health 
insurance in Japan.  
Prescription record 
Because of a limited time period for the study, we did not adopt ATC for drug names 
written in text in the form (Appendix 2). Ideally, ATC codes would have been assigned 
for each drug based on information on ingredients or combinations of ingredients. 
This would have meant that results could be compared more closely with those of 
other studies. 
Dietary supplements and health foods 
Information on dietary supplements and health foods was collected in the Brown Bag 
Programme in Hiroshima from October to December in 2009, and over half of the 
participants consumed 1 or more products (Kusama, 2010). In Western countries, 
there is an increasing interest in the clinical benefits and risks of dietary supplements 
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such as vitamins and herbal products as a part of complementary and alternative 
medicine (CAM) (Talor et al. 2006). However, information on the interaction between 
conventional medicines and CAM is insufficient, and knowledge of CAM from 
laboratory analysis is inadequate (Fugh-Berman, 2000). Some dietary supplements 
have known interactions with pharmaceutical drugs, and some may have unknown 
risks. Since some potential prescription drug–CAM interactions have been observed 
in the emergency department, further research is required in this field, and 
discussion on the use of CAM between patients and physicians is recommended 
(Taylor et al. 2006). In this study, the pattern of CAM use was not reviewed because 
of its complexity and because of uncertainty about the health impacts of CAM. There 
was also a lack of information on CAM products.  
However, as the aim of reviewing polypharmacy is to reduce the risk of harm, future 
discussions on the definition on polypharmacy should look at whether to include 
CAM, which has potential interactions with pharmaceutical drugs.  
Socioeconomic factors 
Possible socio-economic factors such as economic status, level of education, 
household income, and employment status (Obudanjo et al. 2004; Perry and Tuner, 
2001 cited in Junis-Walker et al. 2006; Rozenfeld et al. 2008) were not covered in this 
study. It is not common in Japan for pharmacists to ask patients for details about 
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socio-economic status, and this data is not usually collected via medical/dispensing 
records. However, it is necessary to keep in mind that socio-economic status, which 
can influence factors including health insurance, access to licenced medicines, and 
health status of a patient, could result in different drug use patterns. Moreover, each 
country needs to investigate the drug use patterns accompanying polypharmacy 
within their own social and clinical setting.  
Type of medical facility 
When a patient receives prescriptions from 1 hospital only, all the whole medications 
can be reviewed at one time regardless of the number of diseases. On the other hand, 
when a patient visits one clinic, multiple diseases are unlikely treated. Therefore, 
„visiting 1 medical facility‟ could have different implications, depending on whether it 
was a hospital or a clinic that was visited. However, the type of medical facility, such 
as „hospital‟ or „clinic‟, could not be distinguished in the Brown Bag Programme, and 
„the number of medical facilities‟ was not selected as a predictor of polypharmacy, in 
this study. 
Qualitative perspectives 
It may be useful to investigate prescribers‟ views on polypharmacy, although, it is 
also natural for physicians to prescribe several medicines as necessary.  
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5 Conclusions 
This study is the first to research predictors of polypharmacy among elderly 
Japanese outpatients using MUR. The results indicated that older people in 
Hiroshima consumed an average of 7 prescribed and OTC drugs in 2009. When 
prescribing medicines to the elderly, doctors should consider the possibility of 
polypharmacy and its predictors such as severity of health condition, and the use of 
drugs for other concurrent conditions, such as antihypertension drugs. Whether age 
is a predictor of polypharmacy is open to discussion. Considering the prevalence of 
COPD and its pharmacotherapy seen in other studies, Japan may need to monitor 
COPD as a potential significant predictor of polypharmacy in the Japanese 
population in the future. Some types of drugs were identified as predictors of 
polypharmacy; these included drugs acting on the cardiovascular and digestive 
organs, the central nervous system, and urogenital and anal organs. Anti-allergy 
agents, blood and body fluid agents, vitamins, and traditional Chinese medicines 
were also identified as predictors of polypharmacy.  
Although Japan consumes more drugs per person than other countries, prescribing 
multiple medicines is not necessarily wrong. The essential aspect is for the 
medication regimen to be appropriate for the patient. MUR could be an effective way 
to improve medication use and check polypharmacy status, including OTC drugs and 
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CAMs. While MUR at time of dispensing is recognised as the pharmacist‟s role in 
Japan, MUR might be an additional clinical service in the future required by patients 
who need „to improve understanding of their medicines; to identify any problematic 
side effects and propose solutions where appropriate; to improve patient compliance 
in taking their medicines (NHS PCC, 2007)‟.  
 
6 Reccomendations 
To promote better quality of life for the elderly and reduce the ill effects of drug use, 
this study suggests that possible factors related to polypharmacy for this group be 
closely monitored. One approach is to review polypharmacy via pharmacists. Action 
to be taken should meet public health needs for an actively aging population as 
proposed by the WHO (n.d.a).  
*Healthcare professionals should bear in mind that elderly Japanese people 
consume more drugs than elderly people in other countries. 
*Healthcare providers in Japan should carefully monitor elderly patients‟ use of OTC 
drugs, „digestive organ agents‟, 'hormones', and 'anti-allergic agents' to reduce their 
risk of harm through polypharmacy. 
*Patients on polypharmacy are at higher risk of drug–drug interactions and 
duplications than those who are not. 
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*Community pharmacists in Japan should conduct medicine use reviews as part of 
their routine work of prescription.  
 
This study highlights the needs for future public health research as follows: 
*A study using the same approach but with a larger population and with a variety of 
variables (e.g. socio-economic, environmental, and educational factors). This would 
help identify predictors of polypharmacy, including COPD/respiratory diseases, as 
seen in other countries. 
*Further research and investigation are necessary to validate application of the 
definition of polypharmacy and the Charlson Comorbidity Index or other indexes as 
adjustment factors in studies in Japan. 
*Qualitative research would be useful to understand the perception and behaviour of 
elderly patients regarding polypharmacy, so as to improve quality of life for this 
group. 
*Actual health outcomes of polypharmacy (e.g. ADR rate) need to be investigated 
with a longitudinal study. 
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Appendix 1: Participant background 
and Feedback sheet 
 Conditions of medication review 
 Recruitment 
 at Pharmacy   at event   
 Others：____________________ 
 Date ＿＿＿＿Year＿＿＿Month＿＿＿Day 
 
Place 
 
 Pharmacy  
（ Counter Private room  
 Partition） 
 Others：＿＿＿＿＿＿＿＿＿ 
 Pharmacist  Name 
 Time 
Review ＿＿＿＿min 
Feedback＿＿＿＿min 
 Feedback  Same day  later  N.A. 
 
Next 
Appointment 
 Yes   No 
 
Participants 
 Age ＿＿＿＿＿ 
 Sex  Male   Female 
 
Insuran
ce type 
 National  Employer  National Old 
 Others：_________________________ 
 Number of medical institute ＿＿＿＿ 
 Self-reported disease conditions 
 
１．Hypertension     ２．Hyperlipidemia 
３．Diabetes         ４．Heart Failure 
５．Gastric abnormal  ６．Osteoporosis 
７．Asthma        ８．Bronchitis 
９．Cystitis      10．Arthritis 
11．Backache    12．Headache 
13．Allergy        14．Eye disorder 
15．Bone fracture 
16．Others_____________________________ 
 
 
Reason for choosing OTC/dietary supplement 
 
 Too busy to go to hospital/see a doctor 
 Feel shy to go to hospital/see a doctor 
 Not serious enough to go to hospital/see a doctor 
 Save money 
 Disease prevention or health maintenance 
 Others：_______________________________ 
 
 
Reason for participation 
 
 Recommended by pharmacist 
 Recommended by family/friends 
 Patient broacher 
 Want to consult with pharmacist 
 Free service (no charge) 
 Others： _______________________________ 
 
 
Participant response 
 Positive 
 Better understand instructions for drug 
use 
 Get confirmation of appropriate 
medications 
 Ease concerns about interaction and 
adverse drug reaction 
 Ease concerns about duplication 
 Others：______________________ 
 
 
 Negative 
 Tiresome to bring all medications from 
home 
 Takes too much time 
 Insufficient advice 
 Others：______________________ 
 
 
 
 
 
Pharmacist advice 
 
 Potential duplication/interaction 
 Drug No.of duplication： 
 Drug No.of interaction： 
 
 
 Overdose/underdose 
 Drug No.： 
 
 
 Potentially inappropriate/unnecessary medication 
use 
 Drug No.： 
 Comment： 
 
 Complicated medication use/risk of less adherence 
 Drug No.： 
 Comment： 
 
 Potential risk of adverse drug reaction 
 Drug No.： 
 Comment： 
Comments on any potential medication problems 
 
 
Appendix 1 and 2 were translated 
version of the formats actually used. 
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Appendix 2: Medication review sheet (for each product) 
Sequential 
No. 
Drug information 
（product name etc.） 
Source 
(Where obtained) 
Duration 
(How long taken) 
Reason for choice 
（OTC・supplement） 
Use in the last week 
Storage Frequency Adherence 
Actions when you forget to 
take the medicine 
  Prescription 
 OTC 
 Dietary supplement 
 
Name：＿＿＿＿＿＿＿＿＿＿＿＿＿＿ 
 
Company：＿＿＿not must＿＿＿＿＿
＿ 
 
Ingredient：＿＿＿＿not must＿＿＿＿
＿ 
 Hospital 
 Pharmacy 
 Retail store 
 Online order 
 Mail order 
 
 Family/friend 
 Others： 
_________________ 
 Less than 
one month 
 One month 
or longer 
 
 
 Unknown 
 
 
 Advertisement 
(TV or magazine) 
 Display in store 
 Recommended in 
store 
 Recommended 
by family member 
 Recommended 
by friends 
 No specific 
reasons 
 Room  
 
Refrigerator 
 Arbitrary 
 
 Others： 
＿_______＿ 
 
＿＿times 
per week 
 
＿＿times 
per day 
 
 as 
needed 
 
 as indicated 
 
 less than 
indicated 
 intentionally 
 missed 
 
 more than 
indicated 
 
 arbitrary 
 Unknown 
 action instructed 
 follow 
 not follow 
 action not instructed 
 no action taken 
 take twice dose at 
next time  
 Others 
＿＿＿＿＿＿＿＿＿＿ 
  Prescription 
 OTC 
 Dietary supplement 
 
Name：＿＿＿＿＿＿＿＿＿＿＿＿＿＿ 
 
Company：＿＿＿not must＿＿＿＿＿
＿ 
 
Ingredient：＿＿＿＿not must＿＿＿＿
＿ 
 Hospital 
 Pharmacy 
 Retail store 
 Online order 
 Mail order 
 
 Family/friend 
 Others： 
_________________ 
 Less than 
one month 
 One month 
or longer 
 
 
 Unknown 
 
 
 Advertisement 
(TV or magazine) 
 Display in store 
 Recommended in 
store 
 Recommended 
by family member 
 Recommended 
by friends 
 No specific 
reasons 
 Room  
 
Refrigerator 
 Arbitrary 
 
 Others： 
＿_______＿ 
 
＿＿times 
per week 
 
＿＿times 
per day 
 
 as 
needed 
 
 as indicated 
 
 less than 
indicated 
 intentionally 
 missed 
 
 more than 
indicated 
 
 arbitrary 
 Unknown 
 action instructed 
 follow 
 not follow 
 action not instructed 
 no action taken 
 take twice dose at 
next time  
 Others 
＿＿＿＿＿＿＿＿＿＿ 
  Prescription 
 OTC 
 Dietary supplement 
 
Name：＿＿＿＿＿＿＿＿＿＿＿＿＿＿ 
 
Company：＿＿＿not must＿＿＿＿＿
＿ 
 
Ingredient：＿＿＿＿not must＿＿＿＿
＿ 
 Hospital 
 Pharmacy 
 Retail store 
 Online order 
 Mail order 
 
 Family/friend 
 Others： 
_________________ 
 Less than 
one month 
 One month 
or longer 
 
 
 Unknown 
 
 
 Advertisement 
(TV or magazine) 
 Display in store 
 Recommended in 
store 
 Recommended 
by family member 
 Recommended 
by friends 
 No specific 
reasons 
 Room  
 
Refrigerator 
 Arbitrary 
 
 Others： 
＿_______＿ 
 
＿＿times 
per week 
 
＿＿times 
per day 
 
 as 
needed 
 
 as indicated 
 
 less than 
indicated 
 intentionally 
 missed 
 
 more than 
indicated 
 
 arbitrary 
 Unknown 
 action instructed 
 follow 
 not follow 
 action not instructed 
 no action taken 
 take twice dose at 
next time  
 Others 
＿＿＿＿＿＿＿＿＿＿ 
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Appendix 3: Hiroshima Brown Bag Programme, Data definition  
(Variables included in this study from Patient Feedback sheet) 
D: Dichotomous  N: Number T: Japanese text 
Element of feedback sheet  Variables Type Sample 
Participant ID   ParticipantID N 10 
Feedback Record ID   FeedbackID T 982 
Patient Age  Patient_Age N 73 
Sex Male Patient_Male D 1 
Female Patient_Female D 0 
Number of medical 
institutes routinely visited 
 Medical_Institute N 2 
Underlying disease Hypertension Medical_Hypertension D 1 
Hyperlipidaemia Medical_Hyperlipidaemia D 0 
Diabets Medical_Diabetes D 0 
Heart failure Medical_Heart failure D 0 
Gastriris, gastric ulser Medical_Gastric D 0 
Osteoporosis Medical_Osteoporosis D 0 
Asthma Medical_Asthma D 0 
Chronic bronchitis Medical_Bronchitis D 0 
Cystitis Medical_Cystitis D 0 
Arthritis Medical_Arthritis D 0 
Low back pain Medical_Backache D 0 
91 
Headache Medical_Headache D 0 
Allergy Medical_Allergy D 0 
Eye disorder Medical_Eye D 0 
Bone fracture Medical_Bone D 0 
Other Medical_Other D 0 
Other(comment) Medical_Comment T あり 
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Appendix 4: Hiroshima Brown Bag Programme, Data definition  
(Variables included in this study from Medication Use Review Sheet) 
D: Dchotonomous  N: NeumericT: Japanese text  
Element of Medication Use Review sheet  Variable Type Sample 
Patient ID    PatientID N 10 
Feedback sheet 
available 
   Feedback D 1 
ID    MedRevID T 0544389 
Sequential 
number of drug 
   DrugSeq N 1 
Product Category Prescription drug  Product_Prescription D 1 
  OTC  Product_OTC D 0 
  Supplement  Product_Supplement D 0 
 Name   Product_Name T ノルバスク
5mg錠 
 Name of Sales 
company 
  Product_Saler T ファイザー 
 Active Ingredient   Product_Ingredient T  
Drug code was assigned to each record based on product name in Japanese text, and added as an independent variable. 
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Appendix 5: IMS Japan K. K., Data definition (Variables included in this study from IMS NPA Data) 
 
Name Variable name Type Length Description Sample 
Drug code DrugID Nominal 11 
Drug code specific to Japan national 
medical insurance claim 
610454024 
ATC4 ATC4 Nominal 20 WHO ATC A10A 
Strength Strength Text 20  100MG 
Dosage form Dosage Nominal 3 
EphMRA New Form Code, Three-letter 
code provided by Pharmaceutical 
market research Association in Europe 
ABA 
Dispensing date DispensingDate Date 8 YYYYMMDD 20091001 
Patient ID PatientID Nominal 13 Encripted Patient ID 7654321 
Sex Sex Nominal 4  F 
Age Age Nominal 5 
Age when drugs for a patient are 
dispensed, stratified by 5 years 
65-59 
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Appendix 6: List of drug classification 
 (1) The MHLW, Japan 
1  Agents affecting nervous system and sensory organs 
   11  Central nervous system agents 
     111  General anesthetics 
     112  Hypnotics and sedatives, anxiolytics 
     113  Antiepileptics 
     114  Antipyretics and analgesics, anti-inflammatory agents 
     115  Stimulants 
     116  Antiparkinsonian agents 
     117  Psychotropics 
     118  Common cold drugs 
     119  Miscellaneous 
   12  Peripheral nervous system agents 
     121  Local anesthetics 
     122  Skeletal muscle relaxants 
     123  Autonomic nervous system agents 
     124  Antispasmodics 
     125  Diaphoretics, anhidrotics 
     129  Miscellaneous 
   13  Sensory organ agents 
     131  Ophthalmic agents 
     132  Otic and nasal agents 
     133  Vertigo agents 
     139  Miscellaneous 
   19  Other agents affecting nervous system and sensory organs 
     190  Other agents affecting nervous system and sensory organs 
 
 2  Agents affecting individual organs 
   21  Cardiovascular agents 
     211  Cardiotonics 
     212  Antiarrhythmic agents 
     213  Diuretics 
     214  Antihypertensives 
     215  Capillary stabilizers 
     216  Vasoconstrictors 
     217  Vasodilators 
     218  Hyperlipidemia agents 
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     219  Miscellaneous 
   22  Respiratory organ agents 
     221  Respiratory stimulants 
     222  Antitussives 
     223  Expectorants 
     224  Antitussives and expectorants 
     225  Bronchodilators 
     226  Gargles 
     229  Miscellaneous 
   23  Digestive organ agents 
     231  Antidiarrheals, intestinal regulators 
     232  Peptic ulcer agents 
     233  Stomachics and digestives 
     234  Antacids 
     235  Purgatives, clysters 
     236  Cholagogues 
     237  Gastrointestinal agents and combinations 
     239  Miscellaneous 
   24  Hormones 
     241  Pituitary hormone preparations 
     242  Salivary gland hormone preparations 
     243  Thyroid and parathyroid hormone preparations 
     244  Anabolic steroid preparations 
     245  Adrenal hormone preparations 
     246  Androgen preparations 
     247  Estrogen and progesterone preparations 
     248  Mixed hormone preparations 
     249  Miscellaneous 
   25  Urogenital and anal organ agents 
     251  Urinary organ agents 
     252  Genital organ agents 
     253  Oxytocics 
     254  Contraceptives 
     255  Hemorrhoidal preparations 
     259  Miscellaneous 
   26  Epidermides 
     261  Antimicrobial agents 
     262  Skin protectants 
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     263  Suppurative dermatosis agents 
     264  Analgesics, anti-itchings, astringents, anti-inflammatory agents 
     265  Antiparasitic dermatosis agents 
     266  Emollients 
     267  Hair remedies 
     268  Bath preparations 
     269  Miscellaneous 
   27  Dental preparations 
     271  Local anesthetics 
     272  Pulp devitalizing agents 
     273  Analgesics and sedatives 
     274  Pulp mummifying agents 
     275  Pulp capping agents 
     276  Antibiotics 
     279  Miscellaneous 
   29  Other agents affecting individual organs 
     290  Other agents affecting individual organs 
 
 3  Agents affecting metabolism 
   31  Vitamins 
     311  Vitamins A and D preparations 
     312  Vitamin B1 preparations 
     313  Vitamin B preparations 
     314  Vitamin C preparations 
     315  Vitamin E preparations 
     316  Vitamin K preparations 
     317  Multivitamin preparations 
     319  Miscellaneous vitamins 
   32  Nutrients, tonics 
     321  Calcium preparations 
     322  Mineral preparations 
     323  Saccharide preparations 
     324  Organic acid preparations 
     325  Protein and amino acid preparations 
     326  Organotherapeutics 
     327  Pediatric agents 
     329  Miscellaneous 
   33  Blood and body fluid agents 
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     331  Blood substitutes 
     332  Hemostatics 
     333  Anticoagulants 
     339  Miscellaneous 
   34  Dialysis agents 
     341  Kidney dialysis agents 
     342  Peritoneal dialysis agents 
     349  Miscellaneous 
   39  Other agents affecting metabolism 
     391  Liver disease agents 
     392  Antidotes 
     393  Habitual intoxication agents 
     394  Gout preparations 
     395  Enzyme preparations 
     396  Antidiabetic agents 
     397  Metabolic disease preparations & combinations 
     399  Miscellaneous 
 
 4  Agents affecting cellular function 
   41  Cellular function activating agents 
     411  Chlorophyll preparations 
     412  Pigment preparations 
     419  Miscellaneous 
   42  Antineoplastics 
     421  Alkylating agents 
     422  Antimetabolites 
     423  Antibiotics 
     424  Plant extract preparations 
     429  Miscellaneous 
   43  Radioactive drugs 
     430  Radioactive drugs 
   44  Allergic agents 
     441  Antihistamines 
     442  Stimulation therapy agents 
     443  Nonspecific immunogen preparations 
     449  Miscellaneous 
   49  Other agents affecting cellular function 
     490  Other agents affecting cellular function 
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 5  Crude drugs and Chinese medicine formulations 
   51  Crude drugs 
     510  Crude drugs 
   52  Traditional Chinese medicines 
     520  Traditional Chinese medicines 
   59  Other crude drugs and Chinese medicine formulations 
     590  Other crude drugs and Chinese medicine formulations 
 
 6  Agents against pathologic organisms and parasites 
   61  Antibiotics 
     611  Acting mainly on gram-positive bacteria 
     612  Acting mainly on gram-negative bacteria 
     613  Acting mainly on gram-positive and gram-negative bacteria 
     614  Acting mainly on gram-positive bacteria and mycoplasma 
     615  Acting mainly on gram-positive bacteria, gram-negative bacteria, 
rickettsia and chlamydia 
     616  Acting mainly on acid-fast bacteria 
     617  Acting mainly on mold 
     619  Miscellaneous 
   62  Chemotherapeutics 
     621  Sulfonamides 
     622  Tuberculosis preparations 
     623  Leprostatics 
     624  Synthetic antibacterials 
     625  Antivirals 
     629  Miscellaneous 
   63  Biological preparations 
     631  Vaccines 
     632  Toxins, toxoids 
     633  Antitoxins, anti-leptospiral sera 
     634  Human blood preparations 
     635  Biological test preparations 
     636  Mixed biological preparations 
     639  Miscellaneous 
   64  Parasitics (systemic) 
     641  Antiprotozoans 
     642  Anthelmintics 
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     649  Miscellaneous 
   69  Other agents against pathogenic organisms and parasites 
     690  Other agents against pathogenic organisms and parasites 
 
 7  Agents not mainly for therapeutic purpose 
   71  Dispensing medicines 
     711  Excipients 
     712  Ointment bases 
     713  Solvents 
     714  Flavorings, deodorants, coloring agents 
     715  Emulsifying agents 
     719  Miscellaneous 
   72  Intracorporeal diagnostic agents 
     721  X-ray contrast media 
     722  Various function testing reagents 
     729  Miscellaneous 
   73  Public health agents 
     731  Antiseptics 
     732  Germicides and disinfectants 
     733  Repellents 
     734  Insecticides 
     735  Rodenticides 
     739  Miscellaneous 
   74  Extracorporeal diagnostic agents 
     741  General testing reagents 
     742  Blood testing reagents 
     743  Biochemical testing reagents 
     744  Serum-immunological testing reagents 
     745  Bacteriological testing reagents 
     746  Patho-tissue testing reagents 
     747  Radioactive medicines 
     749  Miscellaneous 
   79  Other agents not mainly for therapeutic purpose 
     791  Adhesive plasters 
     799  Miscellaneous 
 
 8  Narcotics 
   81  Alkaloidal narcotics 
100 
     811  Opium alkaloids 
     812  Coca alkaloids 
     819  Miscellaneous 
   82  Non-alkaloidal narcotics 
     821  Synthetic narcotics 
     829  Miscellaneous 
   89  Other narcotics 
     890  Other narcotics 
 
(2) WHO  
A: ALIMENTARY TRACT AND METABOLISM 
   A01 STOMATOLOGICAL PREPARATIONS 
   A02 DRUGS FOR ACID RELATED DISORDERS 
   A03 DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS 
   A04 ANTIEMETICS AND ANTINAUSEANTS 
   A05 BILE AND LIVER THERAPY 
   A06 LAXATIVES 
   A07 ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE 
AGENTS 
   A08 ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS 
   A09 DIGESTIVES, INCL. ENZYMES 
   A10 DRUGS USED IN DIABETES 
   A11 VITAMINS 
   A12 MINERAL SUPPLEMENTS 
   A13 TONICS 
   A14 ANABOLIC AGENTS FOR SYSTEMIC USE 
   A15 APPETITE STIMULANTS 
   A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS 
 
B: BLOOD AND BLOOD FORMING ORGANS 
   B01 ANTITHROMBOTIC AGENTS 
   B02 ANTIHEMORRHAGICS 
   B03 ANTIANEMIC PREPARATIONS 
   B05 BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS 
   B06 OTHER HEMATOLOGICAL AGENTS 
 
C: CARDIOVASCULAR SYSTEM 
   C01 CARDIAC THERAPY 
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   C02 ANTIHYPERTENSIVES 
   C03 DIURETICS 
   C04 PERIPHERAL VASODILATORS 
   C05 VASOPROTECTIVES 
   C07 BETA BLOCKING AGENTS 
   C08 CALCIUM CHANNEL BLOCKERS 
   C09 AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM 
   C10 LIPID MODIFYING AGENTS 
 
D: DERMATOLOGICALS 
   D01 ANTIFUNGALS FOR DERMATOLOGICAL USE 
   D02 EMOLLIENTS AND PROTECTIVES 
   D03 PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS 
   D04 ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. 
   D05 ANTIPSORIATICS 
   D06 ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL 
USE 
   D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS 
   D08 ANTISEPTICS AND DISINFECTANTS 
   D09 MEDICATED DRESSINGS 
   D10 ANTI-ACNE PREPARATIONS 
   D11 OTHER DERMATOLOGICAL PREPARATIONS 
 
G: GENITO URINARY SYSTEM AND SEX HORMONES 
   G01 GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS 
   G02 OTHER GYNECOLOGICALS 
   G03 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM 
   G04 UROLOGICALS 
 
H: SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND 
INSULINS 
   H01 PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES 
   H02 CORTICOSTEROIDS FOR SYSTEMIC USE 
   H03 THYROID THERAPY 
   H04 PANCREATIC HORMONES 
   H05 CALCIUM HOMEOSTASIS 
 
J: ANTIINFECTIVES FOR SYSTEMIC USE 
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   J01 ANTIBACTERIALS FOR SYSTEMIC USE 
   J02 ANTIMYCOTICS FOR SYSTEMIC USE 
   J04 ANTIMYCOBACTERIALS 
   J05 ANTIVIRALS FOR SYSTEMIC USE 
   J06 IMMUNE SERA AND IMMUNOGLOBULINS 
   J07 VACCINES 
 
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS 
   L01 ANTINEOPLASTIC AGENTS 
   L02 ENDOCRINE THERAPY 
   L03 IMMUNOSTIMULANTS 
   L04 IMMUNOSUPPRESSANTS 
 
M: MUSCULO-SKELETAL SYSTEM 
   M01 ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS 
   M02 TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN 
   M03 MUSCLE RELAXANTS 
   M04 ANTIGOUT PREPARATIONS 
   M05 DRUGS FOR TREATMENT OF BONE DISEASES 
   M09 OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL 
SYSTEM 
 
N: NERVOUS SYSTEM 
   N01 ANESTHETICS 
   N02 ANALGESICS 
   N03 ANTIEPILEPTICS 
   N04 ANTI-PARKINSON DRUGS 
   N05 PSYCHOLEPTICS 
   N06 PSYCHOANALEPTICS 
   N07 OTHER NERVOUS SYSTEM DRUGS 
 
P: ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS 
   P01 ANTIPROTOZOALS 
   P02 ANTHELMINTICS 
   P03 ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND 
REPELLENTS 
 
R: RESPIRATORY SYSTEM 
103 
   R01 NASAL PREPARATIONS 
   R02 THROAT PREPARATIONS 
   R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES 
   R05 COUGH AND COLD PREPARATIONS 
   R06 ANTIHISTAMINES FOR SYSTEMIC USE 
   R07 OTHER RESPIRATORY SYSTEM PRODUCTS 
 
S: SENSORY ORGANS 
   S01 OPHTHALMOLOGICALS 
   S02 OTOLOGICALS 
   S03 OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS 
 
V: VARIOUS 
   V01 ALLERGENS 
   V03 ALL OTHER THERAPEUTIC PRODUCTS 
   V04 DIAGNOSTIC AGENTS 
   V06 GENERAL NUTRIENTS 
   V07 ALL OTHER NON-THERAPEUTIC PRODUCTS 
   V08 CONTRAST MEDIA 
   V09 DIAGNOSTIC RADIOPHARMACEUTICALS 
   V10 THERAPEUTIC RADIOPHARMACEUTICALS 
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Appendix 7: Results Data 
 
Appendix 7-1: Characteristics of participants of Brown Bag Programme in 
Hiroshima 
 
 Total Non-polyphar
macy N=137 
Polypharmacy 
N=315 
OR (95% CI) 
P value 
Participant (%) 452 137 (30.3) 315 (69.7) - 
Age  Mean (SD) 
      Median 
      Mode  
76.1 
(6.8) 
76.0 
78.0 
74.5 (7.0) 
74.0 
65.0 
76.8 (6.6) 
78.0 
78.0 
- 
p=0.22† 
Sex  Male (%) 
     Female (%) 
153  
299  
 
42 (30.9) 
95 (69.1) 
 
111 (34.8) 
20 (64.9) 
 
0.8 (0.5-1.2) 
P=0.53 
Reference: female 
Number of Disease  
Average (SD) 
  Range 
Median 
   0 
   1 
   2 
   3 
   4 
   5 
   6 
   7 
   8 
 
 
2.9 (1.5) 
0-8 
3 
6  
80 
116  
124  
63 
40 
12 
10  
1 
 
 
1.8 (0.9) 
0-5 
2 
2 (33.3) 
56 (70.0) 
51 (44.0) 
21 (15.3) 
6 (9.5) 
1 (2.5) 
0 
0 
0 
 
 
3.3 (1.5) 
0-8 
3 
4 (66.7) 
24 (30.0) 
65 (56.0) 
103 (83.1) 
57 (90.5) 
39 (99.5) 
12 (100) 
10 (100) 
1 (100) 
 
 
 
P<0.01† 
 
1.0 
0.2 (0.0-1.3) 
0.6 (0.1-3.6) 
2.5 (0.4-14.3) 
4.8 (0.7-31.6) 
19.5 (1.4-265.6) 
- 
- 
- 
Hypertension (%) 275  67 (24.4) 208 (75.6) 
2.0 (1.4-3.1) 
P<0.01 
Hyperlipidaemia (%) 157 43 (27.4) 114 (72.6) 
1.2 (0.8-1.9) 
P=0.32 
Heart Failure (%) 88 16 (18.2) 72 (81.8) 
2.2 (1.2-4.0) 
P=0.01 
Diabetes (%) 61 14 (26.3) 46 (76.7) 
1.5 (0.8-2.8) 
P=0.21 
Gastric Abnormal (%) 109 12 (11.0) 97 (89.0) 
4.6 (2.4-8.8) 
P<0.01 
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 Total Non-polyphar
macy N=137 
Polypharmacy 
N=315 
OR (95% CI) 
P value 
Ospeoporosis (%) 84 14 (16.7) 70 (83.3) 
2.5 (1.4-4.6) 
P<0.01 
Athsma* (%) 25 4 16.0) 21 (84.0) 
2.4 (0.8-7.1) 
P=0.11 
Bronchitis* (%) 9 1 (11.1) 8 (88.9) 
3.5 (0.4-28.6) 
P=0.21 
Cystitis* (%) 7 3 (42.9) 4 (57.1) 
0.6 (0.1-2.6) 
P=0.47 
Arthritis (%) 61 11 (18.3) 49 (81.7) 
2.1 (1.1-4.2) 
P=0.03 
Backache* (%) 72 4 (5.6) 68 (94.4) 
9.2 (3.3-25.6) 
P<0.01 
Headache* (%) 13 1 (7.7) 12 (92.3) 
5.4 (0.7-41.8) 
P=0.07 
Allergy* (%) 36 4 (5.6) 32 (88.9) 
3.8 (1.3-10.8) 
P=0.01 
Eye (%) 92 19 (20.7) 73 (79.3) 
1.9 (1.1-3.2) 
P=0.02 
Bone* (%) 3 0 (0.0) 3 (100.0) - 
Others§(%) 227 53 (23.3) 175 (77.1) - 
†Kruskal-Wallis Test 
*count less than 5 and chi-square test may not be a valid test. 
§various diseases were recorded and each disease was infrequent up to ten. 
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Appendix 7-2: Actual number of Drug use among the Brown Bag Programme 
(1) The level of 3-digit class 
Drug Class Non-poly
pharmacy 
Polypharm
acy 
Total 
112: Hypnotics and sedatives, anxiolytics 20 189 209 
113: Antiepileptics 2 8 10 
114: Antipyretics and analgesics, 
 anti-inflammatory agents 
8 104 112 
116: Antiparkinsonian agents 3 18 21 
117: Psychotropics 14 115 129 
118: Common cold drugs 1 10 11 
119: Miscellaneous 2 9 11 
121: Local anesthetics 0 1 1 
123: Autonomic muscle relaxants 0 5 5 
124: Antispasmodics 1 28 29 
133: Vertigo agents 3 25 28 
211: Cardiotonics 2 15 17 
212: Antiarrhythmic agents 6 28 34 
213: Diuretics 2 45 47 
214: Antihypertensives 42 220 264 
216: Vasoconstrictors 0 1 1 
217: Vasodilators 35 183 218 
218: Hyperlipidemia agents 36 134 170 
219: Miscellaneous 10 39 49 
222: Antitussives 0 6 6 
223: Expectorants 2 33 35 
224: Antitussives and exectorants 0 2 2 
225: Bronchodilators 1 16 17 
229: Miscellaneous 2 3 5 
231: Antidirraheals, intestinal regulators 0 41 41 
232: Peptic ulcer agents 16 270 286 
233: Stomachics and digestives 2 36 38 
234: Antacids 5 50 55 
235: Purgatives, clysters 4 52 56 
236: Cholagogues 0 15 15 
239: Miscellaneous 3 38 41 
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243: Thyroid and parathyroid hormone 
preparations 
1 19 20 
245: Adrenal hormone preparations 0 17 17 
247: Estrogen and progesterone 
preparations 
0 2 2 
249: Miscellaneous 1 5 6 
255: Hemorrhoidal preparations 0 1 1 
259: Miscellaneous 7 54 61 
290: Other agents affecting individual 
organs 
0 2 2 
311: Vitamins A and D preparations 6 42 48 
312: Vitamin B1 preparations 0 10 10 
313: Vitamin B preparations 8 58 66 
314: Vitamin C preparations 0 4 4 
315: Vitamin E preparations  0 4 4 
316: Vitamin K preparations 1 5 6 
317: Multivitamin preparations 0 19 19 
321: Calcium prepatations 0 9 9 
322: Mineral preparations 0 4 4 
325: Protein and amino acid preparations 1 3 4 
332: Hemostatics 0 9 9 
333: Anticoagulants 4 17 21 
339: Miscellaneous (Blood and body fluid 
agents) 
15 123 138 
391: Liver disease agents 0 2 2 
392: Antidotes 1 2 3 
394: Gout preparations 5 22 27 
395: Enzyme preparations 1 3 4 
396: Antidiabetic agents 19 80 99 
399: Miscellaneous (Other agents 
affecting metabolism) 
12 70 82 
422: Antimetabolites 1 1 2 
429: Miscellaneous (Antineoplastics) 4 6 10 
441: Antihistamines  0 8 8 
442: stimulation therapy agents 1 6 7 
449: Miscellaneous (Allergic agents) 6 62 68 
510: Crude drugs 0 2 2 
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520: Traditional Chinese medicines 10 90 100 
590: Other crude drugs and Chinese 
medicine formulations 
0 1 1 
613: Acting mainly on gram-positive and 
gram-negative bacteria 
2 6 8 
614: Acting mainly on gram-positive 
bacteria and mycoplasma 
0 5 5 
621: Sulfonamides 0 6 6 
624: Leprostatics 1 7 8 
629: miscellaneous 
(Chemothrerapeutics) 
1 3 4 
Prescription 311 2554 2865 
OTC 49 221 270 
Total drug records 389 2933 3322 
Number of Participant 132 320 452 
 
No patients observed in non-polypharmacy group: 121, 123, 216, 222, 224, 231, 236, 245, 
247, 255, 290, 312, 314, 315, 317, 321, 322, 332, 391, 441, 510, 590, 614, 621.  
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(2) The level of 2-digit class 
    
 
 
11: Central nervous system agents, 12: Peripheral nervous system agents, 13: Sensory 
organ agents, 21: Cardiovascular agents, 22: Respiratory organ agents, 23: Digestive 
organ agents, 24: Hormones, 25: Urogenital and anal organ agents, 29: Other agents 
affecting individual organs, 31: Vitamins, 32: Nutrients and tonics, 33: Blood and body fluid 
agents, 39: Other agents affecting metabolism, 42: Antineoplastics, 44: Allergic agents, 
51: Crude drugs, 52: Traditional Chinese medicines, 61: Antibiotics, 62: 
Chemotherapeutics, NOS: Not other specified drugs, OTC: Over-the-counter drugs 
  
110 
Appendix 7-3: Profile of Medicines Use in the study population of Brown Bag 
Programme  
(Total≥50) 
Japan Drug category with code (WHO 
ATC code) 
Non-polyphar
macy 
(N=137) 
Polypharmacy 
(N=315) 
Total (N=452) 
OR (95%CI) 
112  Hypnotics and sedatives, 
anxiolytics (N05B, N05C) 
19 129 148 
4.3 (2.5-7.3) 
114  Antipyretics and analgesics, 
anti-inflammatory agents (N02B) 
8 86 94 
6.1 (2.8-12.9) 
117  Psychotropics (N05A,  N06A) 13 87 100 
3.6 (2.0-6.8) 
214  Antihypertensives (C02A, C02B, 
C02C, C02D, C08C,C09A,C09B, 
C09C, C09D, C09X) 
39 162 201 
2.7 (1.7-4.1) 
217  Vasodilators (C01D, C04A, 
C07E) 
34 158 192 
3.0 (2.0-4.8) 
218 Hyperlipidemia agents (C10A, 
C10B) 
34 127 161 
2.0 (1.3-3.2) 
232 Peptic ulser gents (A02B) 14 188 202 
13.0 (7.2-23.6) 
234 Antacids (A02A) 5 48 53 
4.7 (1.8-12.2) 
235 Purgatives, clysters (N.A.) 4 46 50 
5.7 (2.0-16.1) 
259 Urogenital and anal organ agents, 
Miscellaneous (N.A.) 
7 49 56 
3.4 (1.5-7.8) 
313 Vitamin B preparations (A11E) 8 53 61 
3.3 (1.5-7.1) 
339 Miscellaneous: Blood and body 
fluid agents (V07AC) 
15 100 115 
3.8 (2.1-6.8) 
396  Antidiabetic agents (A10) 15 48 63 
1.5 (0.8-.2.7) 
449 Allergic agents, Miscellaneous 
(N.A.) 
6 56 62 
4.7 (2.0-11.2) 
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520  Traditional Chinese medicines 
(not available) 
10 69 79 
3.6 (1.8-7.2) 
Not otherwise specified prescription 
drugs 
9 106 115 
7.2 (3.5-14.7) 
Over-the-counter drugs 39 131 170 
1.8 (1.2-2.6) 
 
Appendix 7-4: Age distribution 
(1) Participant Age (Total) 
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(2) Patient Age (non-polypharmacy) 
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(3) Patient Age (polypharmacy) 
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Appendix 7-5: Distribution of the number of visiting medical facilities 
 
(1) Number of visiting medical facilities (Total) 
 
 
 
(2) Number of visiting medical facilities (non-polypharmacy) 
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(3) Number of visiting medical facilities (polypharmacy) 
 
 
 
Appendix 7-6: Distribution of Carlson Comorbidity Index 
(1) Charlson Comorbidity Index (Total) 
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(2) Charlson Disease Index (non-polypharmacy) 
 
 
 
(3) Charlson Disease Index (polypharmacy) 
 
 
  
117 
 
Appendix 7-7: Distribution of comorbidities 
(1) Distribution of number of comorbidities (Total)  
 
 
(2) Distribution of number of comorbidities (non-polypharmacy) 
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(3) Distribution of number of comorbidities (polypharmacy) 
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Appendix 7-8 Correlation Coefficient between independent variables 
_NAME_ poly-
phar-
macy 
Age 
class 
Female medinst
t 
CCI 
class 
j11 j12 j13 j21 j22 j23 j24 j25 j29 
polypharmacy 1.00  0.17  -0.04  0.28  0.29  0.39  0.17  0.09  0.21  0.16  0.52  0.17  0.15  0.04  
Age_class 0.17  1.00  0.02  0.17  0.10  0.01  -0.01  0.04  0.10  0.06  0.18  0.04  0.16  -0.07  
Female -0.04  0.02  1.00  0.00  -0.06  0.07  0.01  0.02  -0.06  -0.04  0.00  0.04  -0.25  0.05  
medinstt 0.28  0.17  0.00  1.00  0.13  0.11  0.10  0.15  0.09  0.03  0.30  0.17  0.16  -0.01  
CCI class 0.29  0.10  -0.06  0.13  1.00  0.09  0.05  0.08  0.08  0.10  0.25  0.05  0.07  0.05  
j11 0.39  0.01  0.07  0.11  0.09  1.00  0.17  0.09  0.00  0.01  0.33  0.10  0.07  0.06  
j12 0.17  -0.01  0.01  0.10  0.05  0.17  1.00  0.08  0.01  0.03  0.18  0.00  -0.01  -0.02  
j13 0.09  0.04  0.02  0.15  0.08  0.09  0.08  1.00  0.08  0.01  0.13  0.07  -0.03  -0.02  
j21 0.21  0.10  -0.06  0.09  0.08  0.00  0.01  0.08  1.00  0.02  0.04  -0.01  0.01  0.04  
j22 0.16  0.06  -0.04  0.03  0.10  0.01  0.03  0.01  0.02  1.00  0.11  0.07  0.04  -0.02  
j23 0.52  0.18  0.00  0.30  0.25  0.33  0.18  0.13  0.04  0.11  1.00  0.14  0.18  -0.01  
j24 0.17  0.04  0.04  0.17  0.05  0.10  0.00  0.07  -0.01  0.07  0.14  1.00  -0.02  0.10  
j25 0.15  0.16  -0.25  0.16  0.07  0.07  -0.01  -0.03  0.01  0.04  0.18  -0.02  1.00  -0.03  
j29 0.04  -0.07  0.05  -0.01  0.05  0.06  -0.02  -0.02  0.04  -0.02  -0.01  0.10  -0.03  1.00  
j31 0.26  0.17  0.11  0.19  0.05  0.14  0.07  0.09  0.04  0.07  0.20  0.08  0.02  0.03  
j32 0.10  0.04  0.04  0.03  0.00  0.02  -0.06  0.06  -0.02  0.05  0.02  0.11  0.07  0.17  
j33 0.23  0.07  -0.08  0.12  0.10  0.01  0.01  0.04  0.17  0.12  0.06  0.08  0.07  0.10  
j39 0.16  0.05  0.03  0.08  0.18  -0.04  0.07  0.05  -0.09  0.02  0.04  0.01  -0.03  0.02  
j42 -0.04  -0.01  -0.06  0.08  0.01  -0.13  -0.05  0.02  0.02  -0.06  0.00  -0.05  0.02  -0.01  
j44 0.19  0.00  -0.03  0.15  0.05  0.04  0.08  0.03  0.03  0.29  0.10  0.11  0.06  0.06  
j51 0.04  0.01  -0.02  -0.01  0.05  0.06  0.11  -0.02  0.04  -0.02  -0.01  -0.02  -0.03  0.50  
j52 0.18  -0.04  -0.03  0.07  0.06  0.12  0.11  0.10  -0.01  0.05  0.10  0.05  -0.05  0.14  
j59 0.03  -0.03  0.03  
 
0.04  0.04  -0.01  -0.01  0.02  -0.02  0.04  0.15  -0.02  0.00  
j61 0.05  0.04  -0.06  0.04  -0.02  -0.05  0.00  -0.04  0.02  0.26  -0.02  0.05  -0.02  -0.01  
j62 0.08  0.02  -0.06  0.04  0.08  0.06  0.07  0.01  -0.01  0.12  0.08  0.27  0.07  -0.01  
NOS 0.29  0.16  0.11  0.20  0.06  0.10  0.13  0.02  0.00  0.13  0.15  0.06  0.07  -0.04  
otc 0.12  0.06  -0.01  0.01  -0.01  0.01  0.12  0.02  -0.05  0.01  0.02  -0.03  -0.01  -0.05  
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Continued: 
_NAME_ j31 j32 j33 j39 j42 j44 j51 j52 j59 j61 j62 NOS otc 
polyall 0.26  0.10  0.23  0.16  -0.04  0.19  0.04  0.18  0.03  0.05  0.08  0.29  0.12  
age_class 0.17  0.04  0.07  0.05  -0.01  0.00  0.01  -0.04  -0.03  0.04  0.02  0.16  0.06  
Female 0.11  0.04  -0.08  0.03  -0.06  -0.03  -0.02  -0.03  0.03  -0.06  -0.06  0.11  -0.01  
medinstt 0.19  0.03  0.12  0.08  0.08  0.15  -0.01  0.07  
 
0.04  0.04  0.20  0.01  
charlson_class 0.05  0.00  0.10  0.18  0.01  0.05  0.05  0.06  0.04  -0.02  0.08  0.06  -0.01  
j11 0.14  0.02  0.01  -0.04  -0.13  0.04  0.06  0.12  0.04  -0.05  0.06  0.10  0.01  
j12 0.07  -0.06  0.01  0.07  -0.05  0.08  0.11  0.11  -0.01  0.00  0.07  0.13  0.12  
j13 0.09  0.06  0.04  0.05  0.02  0.03  -0.02  0.10  -0.01  -0.04  0.01  0.02  0.02  
j21 0.04  -0.02  0.17  -0.09  0.02  0.03  0.04  -0.01  0.02  0.02  -0.01  0.00  -0.05  
j22 0.07  0.05  0.12  0.02  -0.06  0.29  -0.02  0.05  -0.02  0.26  0.12  0.13  0.01  
j23 0.20  0.02  0.06  0.04  0.00  0.10  -0.01  0.10  0.04  -0.02  0.08  0.15  0.02  
j24 0.08  0.11  0.08  0.01  -0.05  0.11  -0.02  0.05  0.15  0.05  0.27  0.06  -0.03  
j25 0.02  0.07  0.07  -0.03  0.02  0.06  -0.03  -0.05  -0.02  -0.02  0.07  0.07  -0.01  
j29 0.03  0.17  0.10  0.02  -0.01  0.06  0.50  0.14  0.00  -0.01  -0.01  -0.04  -0.05  
j31 1.00  0.09  0.06  0.17  -0.04  0.04  0.10  0.15  -0.03  0.02  0.00  0.19  -0.01  
j32 0.09  1.00  0.03  0.01  0.04  0.02  -0.01  0.07  -0.01  -0.03  0.09  0.08  -0.10  
j33 0.06  0.03  1.00  0.01  -0.05  0.18  0.03  0.06  0.07  0.01  0.05  0.08  0.00  
j39 0.17  0.01  0.01  1.00  -0.03  -0.10  -0.05  -0.11  -0.03  -0.03  -0.05  0.06  -0.05  
j42 -0.04  0.04  -0.05  -0.03  1.00  -0.03  -0.01  0.03  -0.01  -0.03  -0.03  -0.10  -0.01  
j44 0.04  0.02  0.18  -0.10  -0.03  1.00  0.16  0.08  -0.02  0.20  0.11  0.13  0.00  
j51 0.10  -0.01  0.03  -0.05  -0.01  0.16  1.00  0.14  0.00  0.20  -0.01  -0.04  0.02  
j52 0.15  0.07  0.06  -0.11  0.03  0.08  0.14  1.00  -0.02  0.11  -0.03  0.11  0.00  
j59 -0.03  -0.01  0.07  -0.03  -0.01  -0.02  0.00  -0.02  1.00  -0.01  -0.01  -0.03  -0.04  
j61 0.02  -0.03  0.01  -0.03  -0.03  0.20  0.20  0.11  -0.01  1.00  0.04  0.03  0.01  
j62 0.00  0.09  0.05  -0.05  -0.03  0.11  -0.01  -0.03  -0.01  0.04  1.00  0.07  0.01  
NOS 0.19  0.08  0.08  0.06  -0.10  0.13  -0.04  0.11  -0.03  0.03  0.07  1.00  0.01  
otc -0.01  -0.10  0.00  -0.05  -0.01  0.00  0.02  0.00  -0.04  0.01  0.01  0.01  1.00  
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J11: Central nervous system agents, J12: Peripheral nervous system agents, J13: Sensory organ agents, J21: Cardiovascular agents, J22: 
Respiratory organ agents, J23: Digestive organ agents, J24: Hormones, J25: Urogenital and anal organ agents, J29: Other agents affecting 
individual organs, J31: Vitamins, J32: Nutrients and tonics, J33: Blood and body fluid agents, J39: Other agents affecting metabolism, J42: 
Antineoplastics, J44: Allergic agents, J51: Crude drugs, J52: Traditional Chinese medicines, J61: Antibiotics, J62: Chemotherapeutics, OTC: 
Over-the-counter drugs 
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Appendix 7-9: SAS Datasetand SAS Procedure 
Dataset „Logit‟ 
ParticipantID Participant ID 
Age_class Age class, 1=65-69, 2=70-74, 3=75-79, 4=80-84, 5=85-89, 6=90≤ 
Patient_Female Male=0, female=1 
Medinstt Number of visitng medical facilities= 1, 2≤ 
Charlson_class Charlson Comorbidity Index= 0, 1≤ 
J11 Central nervous system agents 
J12 Peripheral nervous system agents 
J13 Sensory organ agents 
J21 Cardiovascular agents  
J22 Respiratory organ agents 
J23 Digestive organ agents 
J24 Hormones 
J25 Urogenital and anal organ agents 
J29 Other agents affecting individual organs 
J31 Vitamins 
J32 Nutrients, tonics 
J33 Blood and body fluid agents 
J39 Other agents affecting metabolism 
J42 Antineoplastics 
J44 Allergic agents  
J51 Crude drugs 
J52 Traditional Chinese medicines. 
J61 Antibiotics 
J62 Chemotherapeutics 
OTC Over-the-counter drugs 
[SAS Proceduer] 
proc logistic data=logit ; 
class age_class (ref='1') /param=ref; 
class medinstt (ref='1') /param=ref; 
class charlson_class (ref='0') /param=ref; 
model polyall(event='1')= age_class Patient_Female medinstt charlson_class           
                       j11 j12 j13 j19 j21 j22 j23 j24 j25 j26 j27 j29 j31 j32 j33 j34 j39  
                       j41 j42 j43 j44 j49 j51 j52 j59 j61 j62 j63 j64 j69 otc  
                    / selection=stepwise slentry=0.20 slstay=0.20 details lackfit; 
output out=cook c=c; 
score out=score;  
run;  
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Appendix 7-10: Output of Logistic Regression  
 
„Point Estimate‟ indicates regression coefficient. 
 
 
  All variables were less than 0.2 of probability. 
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  Nine variables (age class, number of medical facilities, j13, j22, j29, j42, j51, j61, j62) 
were removed from the model. 
J11: Central nervous system agents, J12: Peripheral nervous system agents, J13: 
Sensory organ agents, J21: Cardiovascular agents, J22: Respiratory organ agents, J23: 
Digestive organ agents, J24: Hormones, J25: Urogenital and anal organ agents, J29: 
Other agents affecting individual organs, J31: Vitamins, J32: Nutrients and tonics, J33: 
Blood and body fluid agents, J39: Other agents affecting metabolism, J42: Antineoplastics, 
J44: Allergic agents, J51: Crude drugs, J52: Traditional Chinese medicines, J61: 
Antibiotics, J62: Chemotherapeutics, OTC: Over-the-counter drugs 
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Appendix 7-11: The contingency table with observed and estimated numbers of 
observation 
Estimate  
Observed 
Total polypharmacy Non-polypharmacy 
Polypharmacy 273 26 299 
Non-polypharmacy 22 99 121 
 299  420 
Positive predictive value = True positives/(True positives+False positives)  
                      = 273/(273+26) = 91.3%.  
Negative predictive value = True negatives/(True negatives+False negatives)  
                       =99/(99+26) = 79.2% 
Sensitivity = True positives/(True positives+False negatives)  
          = 273/(273+22) = 92.5% 
Specificity = True negatives/(True negatives+False posivives)  
          = 99/(99+26) = 81.8% 
 
 
Appendix 7-12: Coook’s distance to identify an outliner 
 
 
 
Observations with Cook‟s distance>1.0: ParticipantID=272, 283 in non-polypharmacy 
group. 
Hosmer and Lemeshow test: 3.8 P=0.87 
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Nomura, Kaori 
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 1 
Drug use patterns and predictors of polypharmacy among elderly , community-residing persons in 
Hiroshima, Japan 
1. Introduction and background 
The elderly in Japan, and elsewhere, consume a disproportionately high amount of health care resources.  Indeed, 45% 
of costs for prescription drugs in Japan in 2007 were for individuals 65 years and above (MHLW, 2009b).  Elderly persons, 
especially those who have high utilization of health care, are at increased risk for polypharmacy (Junius-Walker, 2007; 
Medco, 2009), or the use of multiple medications concurrently (Yasuhara, 1980).  Polypharmacy is an established risk 
factor for adverse drug events resulting from duplication of drugs in the same therapeutic class, drug-drug interactions, 
contraindications and other inappropriate medication use (Fulton and Allen, 2005, Hajjar et al. 2007, Niwata, 2006).  
Though polypharmacy has been described in the inpatient setting in Japan (Koyama, et al. 2003; Suzuki, 2006), the use of 
multiple medications, and the consequent safety issues that may result from using drugs concomitantly, is not well studied 
in the outpatient setting.  The “Brown Bag Programme” was recently implemented in Hiroshima to address the problem of 
polypharmacy in the elderly (Kusama, 2010).  This voluntary initiative permits consumers to bring all their medications 
(prescription and over-the-counter) to community pharmacies for evaluation of potential safety problems.  The proposed 
research will evaluate data from the Hiroshima Brown Bag Programme to explore patterns of drug use among elderly, 
community-dwelling persons in Hiroshima, Japan.  By characterizing drug utilization patterns, this research can help to 
identify predictors or risk factors for polypharmacy and common, potential safety issues related to the concurrent use of 
multiple medications.  
2. Summary of relevant literature 
Koyama et al. (2003) reported that the number of potential drug-drug interactions is correlated with the the number of 
concomitant drugs being taken.  This finding is especially disconcerting given that the authors found that 28% of elderly 
(65+ years) outpatients at a university hospital took six or more medications concurrently. Akazawa et al. (2009) reported 
that based on health insurance claim data 44% of elderly Japanese patients took one or more potentially inappropriate 
medications (PIM). Kusama (2010) reported that elderly participants in the Hiroshima Brown-Bag Programme took, on 
average, 6.6 prescription drugs, 1.6 OTCs and 1.8 supplemental health products.   Furthermore, 62% of the participants 
in this program took more than 5 prescription medicines; 35% regularly used OTC products; and, 53% routinely used 
nutritional supplements. There is a paucity of data on the predictors of polypharmacy in the elderly, especially in Japan.  
Knowledge of the factors that lead patients to use multiple medications concomitantly will be useful in helping to avoid 
potential drug safety issues (e.g., drug-drug interactions) and will also help to ensure a more robust delivery of health care 
resources in the vulnerable elderly population.   
3. Research questions 
(1) What are the patterns of use of prescription and OTC drugs among elderly persons (aged 65 years and above) in 
Hiroshima, Japan?  (2) What are the predictors of polypharmacy, defined as 5 or more drugs taken concurrently, among 
the elderly in Hiroshima, Japan? 
4. Study aim and objectives 
Aim: To describe the patterns and potential safety issues related to prescription and OTC drug use in the elderly in 
Hiroshima, Japan. 
Objectives:  (1) To identify the predictors for polypharmacy in elderly persons in Hiroshima, Japan.   (2) To describe the 
potential for safety issues related to specific drug use patterns (e.g. drug-drug interactions and PIM based on modified 
Beers criteria accommodated to Japan (Imai et al., 2008)) among the elderly in Hiroshima. 
5. Methods 
• Summary of study design:  This is a cross-sectional study of drug utilization in an elderly Japanese cohort. The study 
will be a descriptive analysis to characterize patterns of drug use in elderly outpatients in Hiroshima, Japan. Additionally, the 
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 2 
proposed investigation will consist of an exploratory analysis to determine factors associated with polypharmacy, such as 
demographic variables, drug class, underlying disease/comorbidities, and OTC drug use.   
• Data source:  Name, strength and place of prescription and OTC drug, participant information (age, sex, underlying 
disease.) will be obtained from the Hiroshima Brown Bag Programme conducted from October 2009 to December 2009, 
defined above (Kusama, 2010).  All elderly participants in the Hiroshima Brown Bag Programme will be included in the 
proposed study.  Background of prescription (patient birth year and sex, number of beds and type of department) and 
prescription data (prescription drug name, strength, dose) will be provided from dispensing pharmacies (IMS Japan K.K.). 
The time period of October to December 2009, inclusive, will be used for all data sources in the proposed research study.   
• Data collection and setting 
(1) Data from the Hiroshima Brown Bag Programme are available with approval from University of Tokyo. 
(2) Prescription information of elderly people in Hiroshima will be extracted from a database of prescribed drug information 
by IMS Japan K.K.  
Note that all analyses will be conducted in a home-based office as the data will be transferred to the proposed investigator 
for analysis.   
• Sampling 
(1) Prescription and OTC drug use data are available for all participants over 65 years old (n=460) from the Hiroshima 
Brown Bag Programme.  
(2) Dispensing data of anonymised elderly patients in Hiroshima (IMS Japan K.K.) will be obtained from October 2009 to 
December 2009 synchronised with the Hiroshima Brown Bag Programme. All data will be analysed.  
• Statistical analysis:  A multiple logistic regression model will be fit to identify the predictors of polypharmacy (dependent 
variable, defined as the use of 5 or more medications concurrently).  Independent variables will include age, sex and 
comorbid conditions.  The final model will be evaluated for goodness-of-fit. 
• Statistical Power Calculation:  Given the sample size of 460 patients, the proposed study will have 80% statistical 
power to detect as significant an odds ratio of approximately 1.3 for each standard deviation increase in the mean value of 
a given variable (e.g., age), using an alpha of 0.05, one-tailed test and assuming 35% of patients will meet the outcome (i.e., 
classified as "polypharmacy") (Hsieh, 1989). 
• Expertise available:  Detection on drug-drug interaction will be systematically provided based on regulated drug 
information by an IT vendor company (System Yoshii, Co. Ltd.). Data on prescription drug use will be obtained from a 
proprietary vendor, IMS Japan K.K..  
• Data protection and Confidentiality issues:  All data provided by pharmacies will be anonymised and integrated by 
the research group of University of Tokyo, accredited by Hiroshima Pharmaceutical Association and Regional Health Care 
Council of Hiroshima Prefecture. IMS data dose not contain identification information of patient and doctor. Ethical review 
will be obtained from University of Liverpool. 
6. Research outcomes 
The research will describe the use of prescription and over-the-counter drugs and will identify potential predictors of 
polypharmacy among elderly outpatients in Hiroshima, Japan. It will help health care practitioners in identifying persons at 
increased risk of polypharmacy and the potential health consequences that may result from the use of multiple medications. 
7. Costs 
Data will be provided free of charge by each organisation.  Minimal costs will incur related to the conduct of this research 
including printing costs and telephone expenditures.   
8. Draft timetable 
July –September 2010: Proposal approval, literature review and preparation of translation into English terms 
September-November 2010: Data collection and cleansing, December 2010: Analysis and drafting 
January 2011: Additional analysis and documentation, February 2011: Final draft, March 2011: Submission  
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